Radiotherapy where cytotoxic radionuclides are linked to antibodies in order to deliver toxins directly to tumor targets. Therapy with targeted radiation rather than antibody-targeted toxins (IMMUNOTOXINS) has the advantage that adjacent tumor cells, which lack the appropriate antigenic determinants, can be destroyed by radiation cross-fire. Radioimmunotherapy is sometimes called targeted radiotherapy, but this latter term can also refer to radionuclides linked to non-immune molecules (see RADIOTHERAPY).
Unstable isotopes of yttrium that decay or disintegrate emitting radiation. Y atoms with atomic weights 82-88 and 90-96 are radioactive yttrium isotopes.
Isotopes that exhibit radioactivity and undergo radioactive decay. (From Grant & Hackh's Chemical Dictionary, 5th ed & McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
Rhenium. A metal, atomic number 75, atomic weight 186.2, symbol Re. (Dorland, 28th ed)
Lutetium. An element of the rare earth family of metals. It has the atomic symbol Lu, atomic number 71, and atomic weight 175.
Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes.
Antibodies produced by a single clone of cells.
A class of organic compounds containing a ring structure made up of more than one kind of atom, usually carbon plus another atom. The ring structure can be aromatic or nonaromatic.
The measurement of radiation by photography, as in x-ray film and film badge, by Geiger-Mueller tube, and by SCINTILLATION COUNTING.
Positively charged particles composed of two protons and two NEUTRONS, i.e. equivalent to HELIUM nuclei, which are emitted during disintegration of heavy ISOTOPES. Alpha rays have very strong ionizing power, but weak penetrability.
Unstable isotopes of indium that decay or disintegrate emitting radiation. In atoms with atomic weights 106-112, 113m, 114, and 116-124 are radioactive indium isotopes.
A metallic element that has the atomic symbol Bi, atomic number 83 and atomic weight 208.98.
Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane Ca2+ conductance and thought to play a role in B-cell activation and proliferation.
The total amount of radiation absorbed by tissues as a result of radiotherapy.
Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios.
Unstable isotopes of lead that decay or disintegrate emitting radiation. Pb atoms with atomic weights 194-203, 205, and 209-214 are radioactive lead isotopes.
Astatine. A radioactive halogen with the atomic symbol At, atomic number 85, and atomic weight 210. Its isotopes range in mass number from 200 to 219 and all have an extremely short half-life. Astatine may be of use in the treatment of hyperthyroidism.
A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.
An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
Use of radiolabeled antibodies for diagnostic imaging of neoplasms. Antitumor antibodies are labeled with diverse radionuclides including iodine-131, iodine-123, indium-111, or technetium-99m and injected into the patient. Images are obtained by a scintillation camera.
Actinium. A trivalent radioactive element and the prototypical member of the actinide family. It has the atomic symbol Ac, atomic number 89, and atomic weight 227.0278. Its principal isotope is 227 and decays primarily by beta-emission.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
A 60-kDa extracellular protein of Streptomyces avidinii with four high-affinity biotin binding sites. Unlike AVIDIN, streptavidin has a near neutral isoelectric point and is free of carbohydrate side chains.
Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors.
Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or ANTIGENS. Often the diagnostic or therapeutic substance is a radionuclide. These conjugates are useful tools for specific targeting of DRUGS and RADIOISOTOPES in the CHEMOTHERAPY and RADIOIMMUNOTHERAPY of certain cancers.
Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Semisynthetic conjugates of various toxic molecules, including RADIOACTIVE ISOTOPES and bacterial or plant toxins, with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; and ANTIGENS. The antitumor or antiviral immune substance carries the toxin to the tumor or infected cell where the toxin exerts its poisonous effect.
Ytterbium. An element of the rare earth family of metals. It has the atomic symbol Yb, atomic number 70, and atomic weight 173. Ytterbium has been used in lasers and as a portable x-ray source.
Unstable isotopes of copper that decay or disintegrate emitting radiation. Cu atoms with atomic weights 58-62, 64, and 66-68 are radioactive copper isotopes.
The relationship between the dose of administered radiation and the response of the organism or tissue to the radiation.
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
Transplantation between animals of different species.
A subspecialty of internal medicine concerned with morphology, physiology, and pathology of the blood and blood-forming tissues.
Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.
Neptunium. A radioactive element of the actinide metals family. It has the atomic symbol Np, atomic number 93, and atomic weight 237.
A lectin and cell adhesion molecule found in B-LYMPHOCYTES. It interacts with SIALIC ACIDS and mediates signaling from B-CELL ANTIGEN RECEPTORS.
The amount of radiation energy that is deposited in a unit mass of material, such as tissues of plants or animal. In RADIOTHERAPY, radiation dosage is expressed in gray units (Gy). In RADIOLOGIC HEALTH, the dosage is expressed by the product of absorbed dose (Gy) and quality factor (a function of linear energy transfer), and is called radiation dose equivalent in sievert units (Sv).
Techniques for labeling a substance with a stable or radioactive isotope. It is not used for articles involving labeled substances unless the methods of labeling are substantively discussed. Tracers that may be labeled include chemical substances, cells, or microorganisms.
A water-soluble, enzyme co-factor present in minute amounts in every living cell. It occurs mainly bound to proteins or polypeptides and is abundant in liver, kidney, pancreas, yeast, and milk.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
High energy POSITRONS or ELECTRONS ejected from a disintegrating atomic nucleus.
A class of compounds of the type R-M, where a C atom is joined directly to any other element except H, C, N, O, F, Cl, Br, I, or At. (Grant & Hackh's Chemical Dictionary, 5th ed)
A specific protein in egg albumin that interacts with BIOTIN to render it unavailable to mammals, thereby producing biotin deficiency.
Ring compounds having atoms other than carbon in their nuclei. (Grant & Hackh's Chemical Dictionary, 5th ed)
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
Antibodies obtained from a single clone of cells grown in mice or rats.
Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
Tumors or cancer of the COLON.
Partial immunoglobulin molecules resulting from selective cleavage by proteolytic enzymes or generated through PROTEIN ENGINEERING techniques.
Measurement of radioactivity in the entire human body.
A specialty field of radiology concerned with diagnostic, therapeutic, and investigative use of radioactive compounds in a pharmaceutical form.
Univalent antigen-binding fragments composed of one entire IMMUNOGLOBULIN LIGHT CHAIN and the amino terminal end of one of the IMMUNOGLOBULIN HEAVY CHAINS from the hinge region, linked to each other by disulfide bonds. Fab contains the IMMUNOGLOBULIN VARIABLE REGIONS, which are part of the antigen-binding site, and the first IMMUNOGLOBULIN CONSTANT REGIONS. This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.
Separation systems containing a relatively long-lived parent radionuclide which produces a short-lived daughter in its decay scheme. The daughter can be periodically extracted (milked) by means of an appropriate eluting agent.
"Medicine in Art" refers to the depiction or use of medical themes, practices, or symbolism in various art forms, such as paintings, sculptures, literature, and performing arts, often serving educational, historical, or aesthetic purposes.
An inhibitor of nucleotide metabolism.
The ratio of radiation dosages required to produce identical change based on a formula comparing other types of radiation with that of gamma or roentgen rays.
A cell line derived from cultured tumor cells.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Tumors or cancer of the PERITONEUM.
Presentation of pertinent data by one with special skill or knowledge representing mastery of a particular subject.
A general term for various neoplastic diseases of the lymphoid tissue.
Computer-assisted mathematical calculations of beam angles, intensities of radiation, and duration of irradiation in radiotherapy.
Inbred BALB/c mice are a strain of laboratory mice that have been selectively bred to be genetically identical to each other, making them useful for scientific research and experiments due to their consistent genetic background and predictable responses to various stimuli or treatments.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
The total amount of a chemical, metal or radioactive substance present at any time after absorption in the body of man or animal.
Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells.
A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)
A method of computed tomography that uses radionuclides which emit a single photon of a given energy. The camera is rotated 180 or 360 degrees around the patient to capture images at multiple positions along the arc. The computer is then used to reconstruct the transaxial, sagittal, and coronal images from the 3-dimensional distribution of radionuclides in the organ. The advantages of SPECT are that it can be used to observe biochemical and physiological processes as well as size and volume of the organ. The disadvantage is that, unlike positron-emission tomography where the positron-electron annihilation results in the emission of 2 photons at 180 degrees from each other, SPECT requires physical collimation to line up the photons, which results in the loss of many available photons and hence degrades the image.
Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS.
Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
A group of dominantly and independently inherited antigens associated with the ABO blood factors. They are glycolipids present in plasma and secretions that may adhere to the erythrocytes. The phenotype Le(b) is the result of the interaction of the Le gene Le(a) with the genes for the ABO blood groups.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Rate of energy dissipation along the path of charged particles. In radiobiology and health physics, exposure is measured in kiloelectron volts per micrometer of tissue (keV/micrometer T).
High-molecular weight glycoproteins uniquely expressed on the surface of LEUKOCYTES and their hemopoietic progenitors. They contain a cytoplasmic protein tyrosine phosphatase activity which plays a role in intracellular signaling from the CELL SURFACE RECEPTORS. The CD45 antigens occur as multiple isoforms that result from alternative mRNA splicing and differential usage of three exons.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
Samarium. An element of the rare earth family of metals. It has the atomic symbol Sm, atomic number 62, and atomic weight 150.36. The oxide is used in the control rods of some nuclear reactors.
Small antigenic determinants capable of eliciting an immune response only when coupled to a carrier. Haptens bind to antibodies but by themselves cannot elicit an antibody response.

Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution. (1/835)

Monoclonal antibodies (MoAb) labeled with 90Y are being used for radioimmunotherapy. Because 90Y is a beta emitter, quantitative information from imaging is suboptimal. With the concept of a "matched pair" of isotopes, 111In is used as a surrogate markerfor90Y. We evaluated the differences in biodistribution between 111In- and 90Y-labeled murine antiTac MoAb directed against the IL-2Ralpha receptor. METHODS: The antiTac was conjugated to the 2-(4-isothiocyanatobenzyl)-6-methyl-diethylenetriamine pentaacetic acid (1B4M-DTPA, also known as MX-DTPA). Nine patients with adult T-cell leukemia were treated. Patients received approximately 185 MBq (5 mCi) 111In-labeled antiTac for imaging and 185-555 MBq (5-15 mCi) 90Y-labeled antiTac for therapy. The immunoreactivity of 111In-labeled antiTac was 90%+/-6%, whereas for 90Y-labeled antiTac, it was 74%+/-12%. RESULTS: The differences in blood and plasma kinetics of the two isotopes were small. The area undemeath the blood radioactivity curve was 1.91 percentage+/-0.58 percentage injected dose (%ID) x h/mL for 111In and 1.86%+/-0.64 %ID x h/mL for 90Y. Urinary excretion of 90Y was significantly greater than that of 111In in the first 24 h (P = 0.001), but later, the excretion of 111In was significantly greater (P = 0.001 to P = 0.04). Core biopsies of bone marrow showed a mean of 0.0029+/-0.0012 %ID/g for 111In, whereas the 90Y concentration was 0.0049+/-0.0021 %ID/g. Analyses of activity bound to circulating cells showed concentrations of 500-30,000 molecules of antiTac per cell. When cell-bound activity was corrected for immunoreactive fraction, the ratio of 111In to 90Y in circulating cells was 1.11+/-0.17. Three biopsies of tumor-involved skin showed ratios of 111In to 90Y of 0.7, 0.9 and 1.1. CONCLUSION: This study shows that differences typically ranging from 10% to 15% exist in the biodistribution between 111In- and 90Y-labeled antiTac. Thus, it appears that 111In can be used as a surrogate marker for 90Y when labeling antiTac with the 1 B4M chelate, although underestimates of the bone marrow radiation dose should be anticipated.  (+info)

67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma. (2/835)

Lym-1, a monoclonal antibody that preferentially targets malignant lymphocytes, has induced therapeutic responses and prolonged survival in patients with non-Hodgkin's lymphoma when labeled with 1311. Radiometal-labeled antibodies provide higher tumor radiation doses than corresponding 1311 antibodies. 67Cu has an exceptional combination of properties desirable for radioimmunotherapy, including gamma and beta emissions for imaging and therapy, respectively, a biocompatible half-time and absence of pathways contributing to myelotoxicity. The radioimmunoconjugate, 67Cu-21T-BAT-Lym-1, has been shown to be efficacious in nude mice bearing human Burkitt's lymphoma (Raji) xenografts. Based on these results, a clinical study of the pharmacokinetics and dosimetry of 67Cu-21T-BAT-Lym-1 in patients with lymphoma was initiated. METHODS: Eleven patients with advanced stage 3 or 4 lymphoma were given a preload dose of unmodified Lym-1, then an imaging dose of 126-533 MBq (3.4-14.4 mCi) 67Cu-21T-BAT-Lym-1. Total Lym-1 ranged from 25 to 70 mg dependent on the specific activity of the radioimmunoconjugate and was infused at a rate of 0.5-1 mg/min. Imaging, physical examination, including caliper measurement of superficial tumors, and analysis of blood, urine and fecal samples were performed for a period of 6-13 d after infusion to assess pharmacokinetics, radiation dosimetry, toxicity and tumor regression. RESULTS: In 7 patients, in whom superficial tumors had been accurately measured, tumors regressed from 18% to 75% (mean 48%) within several days of 67Cu-21T-BAT-Lym-1 infusion. The uptake and biological half-time of 67Cu-21T-BAT-Lym-1 in tumors were greater than those of normal tissues, except the mean liver half-time exceeded the mean tumor half-time. The mean tumor-to-marrow radiation ratio was 32:1, tumor-to-total body was 24:1 and tumor-to-liver was 1.5:1. Images were of very good quality; tumors and normal organs were readily identified. Mild and transient Lym-1 toxicity occurred in 6 patients; 1 patient developed a human antimouse antibody. There were no significant changes in blood counts or serum chemistries indicative of radiation toxicity. CONCLUSION: Because of the long residence time of 67Cu-21T-BAT-Lym-1 in tumors, high therapeutic ratios were achieved and, remarkably, numerous tumor regressions were observed after imaging doses. The results indicate considerable therapeutic potential for 67Cu-21T-BAT-Lym-1.  (+info)

67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma. (3/835)

Antilymphoma mouse monoclonal antibody (MoAb) Lym-1, labeled with 67Cu or 131I, has demonstrated promising results in radioimmunotherapy (RIT) for lymphoma. Although 131I has played a central role in RIT thus far, some properties of 67Cu are preferable. A subset of our patients received both 67Cu- and 131I-labeled Lym-1, allowing a comparative evaluation of the two radiopharmaceuticals administered to a matched population of patients. Four patients with B-lymphocytic non-Hodgkin's lymphoma that had progressed despite standard therapy entered trials of 67Cu- and 131I-labeled Lym-1, which were injected 3-26 days apart. Lym-1 was conjugated to 6-[p-(bromoacetamido)benzyl]-1,4,7,11-tetraazacyclotetradecane-N,N ',N",N'"-tetraacetic acid (BAT) via 2-iminothiolane (2IT) and radiolabeled with 67Cu to prepare 67Cu-2IT-BAT-Lym-1; 131I-Lym-1 was preparred by the chloramine-T reaction. Planar imaging was used to quantitate 67Cu-2IT-BAT-Lym-1 or 131I-Lym-1 in organs and tumors daily for 3 days or longer. 67Cu-2IT-BAT-Lym-1 exhibited higher peak concentration in 92% (12 of 13) of tumors and a longer biological half-time in every tumor than 131I-Lym-1. The mean tumor concentration (%ID/g) of 67Cu-2IT-BAT-Lym-1 was 1.7, 2.2, and 2.8 times that of 131I-Lym-1 at 0, 24, and 48 h after injection, respectively. The mean biological half-times of 67Cu-2IT-BAT-Lym-1 and 131I-Lym-1 in tumor were 8.8 and 2.3 days, respectively. Consequently, the mean tumor radiation dose delivered by 67Cu-2IT-BAT-Lym-1 was twice that of 131I-Lym-1, 2.8 (range 0.8-6.7), and 1.4 (range 0.4-35) Gy/GBq, respectively. 67Cu-2IT-BAT-Lym-1 delivered a lower marrow radiation dose than 131I-Lym-1; hence, the tumor:marrow therapeutic indices were 29 and 9.7, respectively. Radiation doses from 67Cu-2IT-BAT-Lym-1 and 131I-Lym-1 to normal tissues were similar except for liver, which received a higher dose from 67Cu-2IT-BAT-Lym-1. Images obtained with 67Cu-2IT-BAT-Lym-1 were superior. Radiation dosimetry data for 67Cu-2IT-BAT-Lym-1 and 131I-Lym-1 agreed with corresponding data from the larger populations of patients from which the matched population for the current study was drawn. In conclusion, 67Cu-2IT-BAT-Lym-1 given to non-Hodgkin's lymphoma patients in close temporal proximity to 131I-Lym-1 exhibited greater uptake and longer retention in tumor, resulting in higher radiation dose and therapeutic index than 131I-Lym-1. These as well as other factors suggest that 67Cu-2IT-BAT-Lym-1 may be superior to 131I-Lym-1 for RIT.  (+info)

Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose radioimmunotherapy. (4/835)

Tumor uptake of the chimeric G250 (cG250) monoclonal antibody (mAb) in patients with primary renal cell carcinoma (RCC) is among the highest reported in solid tumors. However, as observed in other tumor types, the intratumoral distribution of the antibody is highly heterogeneous, which may limit the efficacy of radioimmunotherapy. A number of highly dynamic physiological factors have been postulated that may contribute to heterogeneous tumor uptake of antibodies. Their impact on tumor uptake of antibodies may vary from one tumor region to another as well as from one day to the next. Here, we report on a clinical study that was designed to investigate whether the pattern of mAb cG250 uptake within RCC tumors is altered with subsequent injections. Ten patients with a clinical diagnosis of primary RCC were studied. Nine days before surgery, patients received 125I-cG250 (5 mg of cG250, 50 microCi of 125I), followed by a second injection of 131I-cG250 (5 mg of cG250, 3.5 mCi of 131I) 4 days later. Postsurgery, the tumor was cut into (1-cm) thick slices. Slices were imaged on a gamma camera, and the slice with the most pronounced heterogeneity in 131I-cG250 distribution was selected and cut into 1-cm3 cubes. Each cube was analyzed for 121I-cG250 and 131I-cG250 uptake, and the 131I/125I ratio was determined. For each tumor slice, the distribution patterns of both isotopes were reconstructed and compared with each other. All tumors analyzed showed a heterogeneous distribution of both isotopes throughout the tumor slice; focal uptake in some areas of a tumor reached very high levels (up to 0.19% injected dose/g), whereas other tumorous areas of the same slice showed much lower uptake (as low as 0.0047% injected dose/g). Remarkably, in all tumors, the distribution pattern of both injections was identical: without exception, in all samples analyzed (n = 692), the uptake of 125I-cG250 was similar to 131I-cG250 uptake. Overall, the 131I/125I ratio was 1.64+/-0.31 (mean+/-SD). The constant 131I/125I ratios, observed in all tumor samples investigated, indicate that the tumor parameters governing cG250 mAb uptake were not altered significantly within the time period studied. In addition, the results of this study suggest that multiple radiolabeled antibody injections, administered within short time periods, will target the same areas within a tumor and, thus, will not solve the problem of heterogeneous tumor uptake of antibody.  (+info)

Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors. (5/835)

The objective of this study was to perform the dosimetry of 131I-labeled 81C6 monoclonal antibody (MAb) in patients with recurrent malignant brain tumors, treated by direct injections of MAb into surgically created resection cavities (SCRCs). METHODS: Absorbed dose estimates were performed for nine patients. Dosimetry was performed retrospectively using probe counts (during patient isolation) and whole-body and SPECT images thereafter. Absorbed doses were calculated for the SCRC interface and for regions of interest (ROIs) 1 and 2 cm thick, measured from the margins of cavity interface. Also, mean absorbed doses were calculated for normal brain, liver, spleen, thyroid gland, stomach, bone marrow and whole body. The average residence time for the SCRC was 111 h (65-200h). RESULTS: The average absorbed dose per unit injected activity (range) to the SCRC interface and ROIs 1 and 2 cm thick from the cavity interface were 31.9 (7.8-84.2), 1.9 (0.7-3.6) and 1.0 (0.4-1.8) cGy/MBq, respectively. Average absorbed doses per unit administered activity to brain, liver, spleen, thyroid, stomach, bone marrow and whole body were 0.18, 0.03, 0.08, 0.05, 0.02, 0.02 and 0.01 cGy/MBq, respectively. The high absorbed dose delivered to the SCRC interface may have produced an increase in cavity volume independent of tumor progression. CONCLUSION: At the maximum tolerated dose of 3700 MBq 131I-labeled 81C6 MAb, the absorbed doses to the SCRC interface and ROIs of 1 and 2 cm thickness were estimated to be 1180, 71 and 39 Gy, respectively. The estimated average absorbed dose to the brain was 6.5 Gy. There was no neurological toxicity and minimal hematologic toxicity at this maximum tolerated administration level.  (+info)

Intratumoral distribution of radiolabeled antibody and radioimmunotherapy in experimental liver metastases model of nude mouse. (6/835)

The biodistribution and intratumoral distribution of radiolabeled anticarcinoembryonic antigen (CEA) monoclonal antibody in experimental liver metastases and the therapeutic effect of 131I-labeled anti-CEA antibody on the metastases were studied. METHODS: Three weeks after an intrasplenic injection of human colon cancer cells, mice received an intravenous injection of 125I- or 111In-labeled anti-CEA antibody F33-104. The biodistribution and tumor penetration of radiolabeled antibody were examined by using quantitative autoradiography. To evaluate the therapeutic effect, 5.55, 9.25 or 11.1 MBq (150, 250 or 300 microCi) 131I-labeled F33-104 were injected into groups of mice that had micrometastases smaller than 1 mm. Control groups were injected with phosphate-buffered saline or 131I-labeled control antibody. Mice were killed 3 wk later to determine the size of liver metastases. RESULTS: 1251-labeled F33-104 showed a high accumulation in the liver metastases (percentage of injected dose per gram of metastases [%ID/g] >24%, metastasis-to-liver ratio >9.8, metastasis-to-blood ratio >2.1); however, its accumulation was heterogeneous or peripheral in the nodules more than 1 mm in diameter. When the antibody dose was increased, antibody penetration was improved, but tumor uptake of radioactivity and specificity ratios decreased. In mice with large metastases, radioactivity in the normal tissue was lower than that in mice with small metastases, resulting in higher metastasis-to-background ratios. 111In-labeled antibody showed even higher tumor uptake than 125I-labeled antibody (>51 %ID/g). Metastases formation was suppressed in a dose-dependent manner by 131I-labeled F33-104 injection (5 of 8 mice had no macroscopic tumor after an injection of 5.55 MBq (150 microCi), and all mice had no visible metastasis after an injection of 9.25 or 11.1 MBq [250 or 300 microCi]), whereas tumor progression was seen in the control groups. CONCLUSION: Liver metastases had easy accessibility to the antibody. Micrometastases of less than 0.5 mm in diameter showed homogeneous intratumoral distribution of injected antibody and were successfully treated with 131I-labeled antibody. Very high uptake and satisfactory metastasis-to-liver ratios with 111In-labeled antibody suggest that the use of a radiometal with high beta-energy, such as 90Y or 188Re, is preferable for the successful radioimmunotherapy of metastases larger than 1 mm.  (+info)

Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity. (7/835)

The tumor-associated glycoprotein 72 (TAG-72) antigen is present on a high percentage of tumor types including ovarian carcinomas. Antibody B72.3 is a murine monoclonal recognizing the surface domain of the TAG-72 antigen and has been widely used in human clinical trials. After our initial encouraging studies (M. G. Rosenblum et al., J. Natl. Cancer Inst., 83: 1629-1636, 1991) of tissue disposition, metabolism, and pharmacokinetics in 9 patients with ovarian cancer, we designed an escalating dose, multi-arm Phase I study of 90Y-labeled B72.3 i.p. administration. In the first arm of the study, patients (3 pts/dose level) received an i.p. infusion of either 2 or 10 mg of B72.3 labeled with either 1, 10, 15, or 25 mCi of 90Y. Pharmacokinetic studies demonstrated that concentrations of 90Y-labeled B72.3 persist in peritoneal fluid with half-lives >24 h after i.p. administration. In addition, 90Y-labeled B72.3 was absorbed rapidly into the plasma with peak levels achieved within 48 h, and levels declined slowly thereafter. Cumulative urinary excretion of the 90Y label was 10-20% of the administered dose which suggests significant whole-body retention of the radiolabel. Biopsy specimens of bone and marrow obtained at 72 h after administration demonstrated significant content of the label in bone (0.015% of the dose/g) with relatively little in marrow (0.005% of the dose/g). The maximal tolerated dose was determined to be 10 mCi because of hematological toxicity and platelet suppression. This typically occurred on the 29th day after administration and was thought to be a consequence of the irradiation of the marrow from the bony deposition of the radiolabel. In an effort to suppress the bone uptake of 90Y, patients were treated with a continuous i.v. infusion of EDTA (25 mg/kg/12 h x 6) infused immediately before i.p. administration of the radiolabeled antibody. Patients (3 pts/dose level) were treated with doses of 10, 15, 20, 25, 30, 35, 40, or 45 mCi of 90Y-labeled B72.3 for a total of 38 patients. EDTA administration resulted in significant myeloprotection, which allowed escalation to the maximal tolerated dose of 40 mCi. Dose-limiting toxicity was thrombocytopenia and neutropenia. Studies of plasma and peritoneal fluid pharmacokinetics demonstrate no changes compared with patients without EDTA pretreatment. Cumulative urinary excretion of the radiolabel was not increased in patients pretreated with EDTA compared with the untreated group. However, analysis of biopsy specimens of bone and marrow demonstrated that bone and marrow content of the 90Y label was 15-fold lower (<0.001% injected dose/g) than a companion group without EDTA. Four responses were noted in patients who received 15-30 mCi of 90Y-labeled B72.3 with response durations of 1-12 months. These results demonstrate the myeloprotective ability of EDTA, which allows safe i.p. administration of higher doses of 90Y-labeled B72.3 and, therefore, clearly warrant an expanded Phase II trial in patients with minimal residual disease after standard chemotherapy or for the palliation of refractory ascites.  (+info)

High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model. (8/835)

Recent studies suggest that radioimmunotherapy (RIT) with high-linear energy transfer (LET) radiation may have therapeutic advantages over conventional low-LET (e.g., beta-) emissions. Furthermore, fragments may be more effective in controlling tumor growth than complete IgG. However, to the best of our knowledge, no investigators have attempted a direct comparison of the therapeutic efficacy and toxicity of a systemic targeted therapeutic strategy, using high-LET alpha versus low-LET beta emitters in vivo. The aim of this study was, therefore, to assess the toxicity and antitumor efficacy of RIT with the alpha emitter 213Bi/213Po, as compared to the beta emitter 90Y, linked to a monovalent Fab' fragment in a human colonic cancer xenograft model in nude mice. Biodistribution studies of 213Bi- or 88Y-labeled benzyl-diethylene-triamine-pentaacetate-conjugated Fab' fragments of the murine monoclonal antibody CO17-1A were performed in nude mice bearing s.c. human colon cancer xenografts. 213Bi was readily obtained from an "in-house" 225Ac/213Bi generator. It decays by beta- and 440-keV gamma emission, with a t(1/2) of 45.6 min, as compared to the ultra-short-lived alpha emitter, 213Po (t(1/2) = 4.2 micros). For therapy, the mice were injected either with 213Bi- or 90Y-labeled CO17-1A Fab', whereas control groups were left untreated or were given a radiolabeled irrelevant control antibody. The maximum tolerated dose (MTD) of each agent was determined. The mice were treated with or without inhibition of the renal accretion of antibody fragments by D-lysine (T. M. Behr et al., Cancer Res., 55: 3825-3834, 1995), bone marrow transplantation, or combinations thereof. Myelotoxicity and potential second-organ toxicities, as well as tumor growth, were monitored at weekly intervals. Additionally, the therapeutic efficacy of both 213Bi- and 90Y-labeled CO17-1A Fab' was compared in a GW-39 model metastatic to the liver of nude mice. In accordance with kidney uptake values of as high as > or = 80% of the injected dose per gram, the kidney was the first dose-limiting organ using both 90Y- and 213Bi-labeled Fab' fragments. Application of D-lysine decreased the renal dose by >3-fold. Accordingly, myelotoxicity became dose limiting with both conjugates. By using lysine protection, the MTD of 90Y-Fab' was 250 microCi and the MTD of 213Bi-Fab' was 700 microCi, corresponding to blood doses of 5-8 Gy. Additional bone marrow transplantation allowed for an increase of the MTD of 90Y-Fab' to 400 microCi and for 213Bi-Fab' to 1100 microCi, respectively. At these very dose levels, no biochemical or histological evidence of renal damage was observed (kidney doses of <35 Gy). At equitoxic dosing, 213Bi-labeled Fab' fragments were significantly more effective than the respective 90Y-labeled conjugates. In the metastatic model, all untreated controls died from rapidly progressing hepatic metastases at 6-8 weeks after tumor inoculation, whereas a histologically confirmed cure was observed in 95% of those animals treated with 700 microCi of 213Bi-Fab' 10 days after model induction, which is in contrast to an only 20% cure rate in mice treated with 250 microCi of 90Y-Fab'. These data show that RIT with alpha emitters may be therapeutically more effective than conventional beta emitters. Surprisingly, maximum tolerated blood doses were, at 5-8 Gy, very similar between high-LET alpha and low-LET beta emitters. Due to its short physical half-life, 213Bi appears to be especially suitable for use in conjunction with fast-clearing fragments.  (+info)

Radioimmunotherapy (RIT) is a medical treatment that combines the specificity of antibodies and the therapeutic effects of radiation to target and destroy cancer cells. It involves the use of radioactive isotopes, which are attached to monoclonal antibodies, that recognize and bind to antigens expressed on the surface of cancer cells. Once bound, the radioactivity emitted from the isotope irradiates the cancer cells, causing damage to their DNA and leading to cell death. This targeted approach helps minimize radiation exposure to healthy tissues and reduces side effects compared to conventional radiotherapy techniques. RIT has been used in the treatment of various hematological malignancies, such as non-Hodgkin lymphoma, and is being investigated for solid tumors as well.

Yttrium radioisotopes are radioactive isotopes or variants of the element Yttrium, which is a rare earth metal. These radioisotopes are artificially produced and have unstable nuclei that emit radiation in the form of gamma rays or high-speed particles. Examples of yttrium radioisotopes include Yttrium-90 and Yttrium-86, which are used in medical applications such as radiotherapy for cancer treatment and molecular imaging for diagnostic purposes.

Yttrium-90 is a pure beta emitter with a half-life of 64.1 hours, making it useful for targeted radionuclide therapy. It can be used to treat liver tumors, leukemia, and lymphoma by attaching it to monoclonal antibodies or other targeting agents that selectively bind to cancer cells.

Yttrium-86 is a positron emitter with a half-life of 14.7 hours, making it useful for positron emission tomography (PET) imaging. It can be used to label radiopharmaceuticals and track their distribution in the body, providing information on the location and extent of disease.

It is important to note that handling and use of radioisotopes require specialized training and equipment due to their potential radiation hazards.

Radioisotopes, also known as radioactive isotopes or radionuclides, are variants of chemical elements that have unstable nuclei and emit radiation in the form of alpha particles, beta particles, gamma rays, or conversion electrons. These isotopes are formed when an element's nucleus undergoes natural or artificial radioactive decay.

Radioisotopes can be produced through various processes, including nuclear fission, nuclear fusion, and particle bombardment in a cyclotron or other types of particle accelerators. They have a wide range of applications in medicine, industry, agriculture, research, and energy production. In the medical field, radioisotopes are used for diagnostic imaging, radiation therapy, and in the labeling of molecules for research purposes.

It is important to note that handling and using radioisotopes requires proper training, safety measures, and regulatory compliance due to their ionizing radiation properties, which can pose potential health risks if not handled correctly.

I'm sorry for any confusion, but "Rhenium" is not a medical term. It is a chemical element with the symbol "Re" and atomic number 75. Rhenium is a heavy, silvery-white, metallic element that is highly resistant to corrosion and is used in high-temperature alloys and electronics.

It does not have any direct medical relevance or application as a drug, treatment, or diagnostic tool in human medicine. However, like many other elements, rhenium compounds are being studied for their potential medicinal uses, such as in cancer therapy. But it's important to note that these are still in the research phase and have not yet been approved for use in humans.

Lutetium is a chemical element with the symbol Lu and atomic number 71. It is a rare earth metal that belongs to the lanthanide series. In its pure form, lutetium is a silvery-white metal that is solid at room temperature.

Medically, lutetium is used in the form of radioactive isotopes for diagnostic and therapeutic purposes. For example, lutetium-177 (^177Lu) is a radiopharmaceutical agent that can be used to treat certain types of cancer, such as neuroendocrine tumors. The radioactivity of ^177Lu can be harnessed to destroy cancer cells while minimizing damage to healthy tissue.

It's important to note that the use of lutetium in medical treatments should only be performed under the supervision of trained medical professionals, and with appropriate safety measures in place to protect patients and healthcare workers from radiation exposure.

Iodine radioisotopes are radioactive isotopes of the element iodine, which decays and emits radiation in the form of gamma rays. Some commonly used iodine radioisotopes include I-123, I-125, I-131. These radioisotopes have various medical applications such as in diagnostic imaging, therapy for thyroid disorders, and cancer treatment.

For example, I-131 is commonly used to treat hyperthyroidism and differentiated thyroid cancer due to its ability to destroy thyroid tissue. On the other hand, I-123 is often used in nuclear medicine scans of the thyroid gland because it emits gamma rays that can be detected by a gamma camera, allowing for detailed images of the gland's structure and function.

It is important to note that handling and administering radioisotopes require specialized training and safety precautions due to their radiation-emitting properties.

Monoclonal antibodies are a type of antibody that are identical because they are produced by a single clone of cells. They are laboratory-produced molecules that act like human antibodies in the immune system. They can be designed to attach to specific proteins found on the surface of cancer cells, making them useful for targeting and treating cancer. Monoclonal antibodies can also be used as a therapy for other diseases, such as autoimmune disorders and inflammatory conditions.

Monoclonal antibodies are produced by fusing a single type of immune cell, called a B cell, with a tumor cell to create a hybrid cell, or hybridoma. This hybrid cell is then able to replicate indefinitely, producing a large number of identical copies of the original antibody. These antibodies can be further modified and engineered to enhance their ability to bind to specific targets, increase their stability, and improve their effectiveness as therapeutic agents.

Monoclonal antibodies have several mechanisms of action in cancer therapy. They can directly kill cancer cells by binding to them and triggering an immune response. They can also block the signals that promote cancer growth and survival. Additionally, monoclonal antibodies can be used to deliver drugs or radiation directly to cancer cells, increasing the effectiveness of these treatments while minimizing their side effects on healthy tissues.

Monoclonal antibodies have become an important tool in modern medicine, with several approved for use in cancer therapy and other diseases. They are continuing to be studied and developed as a promising approach to treating a wide range of medical conditions.

Heterocyclic compounds are organic molecules that contain a ring structure made up of at least one atom that is not carbon, known as a heteroatom. These heteroatoms can include nitrogen, oxygen, sulfur, or other elements. In the case of "1-ring" heterocyclic compounds, the molecule contains a single ring structure composed of these heteroatoms and carbon atoms. Examples of 1-ring heterocyclic compounds include pyridine (contains one nitrogen atom in the ring), furan (contains one oxygen atom in the ring), and thiophene (contains one sulfur atom in the ring). These compounds play important roles in various biological processes and are also found in many drugs, dyes, and materials.

Radiometry is the measurement of electromagnetic radiation, including visible light. It quantifies the amount and characteristics of radiant energy in terms of power or intensity, wavelength, direction, and polarization. In medical physics, radiometry is often used to measure therapeutic and diagnostic radiation beams used in various imaging techniques and cancer treatments such as X-rays, gamma rays, and ultraviolet or infrared light. Radiometric measurements are essential for ensuring the safe and effective use of these medical technologies.

Alpha particles are a type of radiation that consist of two protons and two neutrons. They are essentially the nuclei of helium atoms and are produced during the decay of radioactive isotopes, such as uranium or radon. When an alpha particle is emitted from a radioactive atom, it carries away energy and causes the atom to transform into a different element with a lower atomic number and mass number.

Alpha particles have a positive charge and are relatively massive compared to other types of radiation, such as beta particles (which are high-energy electrons) or gamma rays (which are high-energy photons). Because of their charge and mass, alpha particles can cause significant ionization and damage to biological tissue. However, they have a limited range in air and cannot penetrate the outer layers of human skin, making them generally less hazardous than other forms of radiation if exposure is external.

Internal exposure to alpha-emitting radionuclides, however, can be much more dangerous because alpha particles can cause significant damage to cells and DNA when they are emitted inside the body. This is why inhaling or ingesting radioactive materials that emit alpha particles can pose a serious health risk.

Indium radioisotopes refer to specific types of radioactive indium atoms, which are unstable and emit radiation as they decay. Indium is a chemical element with the symbol In and atomic number 49. Its radioisotopes are often used in medical imaging and therapy due to their unique properties.

For instance, one commonly used indium radioisotope is Indium-111 (^111In), which has a half-life of approximately 2.8 days. It emits gamma rays, making it useful for diagnostic imaging techniques such as single-photon emission computed tomography (SPECT). In clinical applications, indium-111 is often attached to specific molecules or antibodies that target particular cells or tissues in the body, allowing medical professionals to monitor biological processes and identify diseases like cancer.

Another example is Indium-113m (^113mIn), which has a half-life of about 99 minutes. It emits low-energy gamma rays and is used as a source for in vivo counting, typically in the form of indium chloride (InCl3) solution. This radioisotope can be used to measure blood flow, ventilation, and other physiological parameters.

It's important to note that handling and using radioisotopes require proper training and safety measures due to their ionizing radiation properties.

Bismuth is a heavy, brittle, white metallic element (symbol: Bi; atomic number: 83) that is found in various minerals and is used in several industrial, medical, and household products. In medicine, bismuth compounds are commonly used as antidiarrheal and anti-ulcer agents due to their antibacterial properties. They can be found in medications like Pepto-Bismol and Kaopectate. It's important to note that bismuth itself is not used medically, but its compounds have medical applications.

CD20 is not a medical definition of an antigen, but rather it is a cell surface marker that helps identify a specific type of white blood cell called B-lymphocytes or B-cells. These cells are part of the adaptive immune system and play a crucial role in producing antibodies to fight off infections.

CD20 is a protein found on the surface of mature B-cells, and it is used as a target for monoclonal antibody therapies in the treatment of certain types of cancer and autoimmune diseases. Rituximab is an example of a monoclonal antibody that targets CD20 and is used to treat conditions such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.

While CD20 itself is not an antigen, it can be recognized by the immune system as a foreign substance when a monoclonal antibody such as rituximab binds to it. This binding can trigger an immune response, leading to the destruction of the B-cells that express CD20 on their surface.

Radiotherapy dosage refers to the total amount of radiation energy that is absorbed by tissues or organs, typically measured in units of Gray (Gy), during a course of radiotherapy treatment. It is the product of the dose rate (the amount of radiation delivered per unit time) and the duration of treatment. The prescribed dosage for cancer treatments can range from a few Gray to more than 70 Gy, depending on the type and location of the tumor, the patient's overall health, and other factors. The goal of radiotherapy is to deliver a sufficient dosage to destroy the cancer cells while minimizing damage to surrounding healthy tissues.

Tissue distribution, in the context of pharmacology and toxicology, refers to the way that a drug or xenobiotic (a chemical substance found within an organism that is not naturally produced by or expected to be present within that organism) is distributed throughout the body's tissues after administration. It describes how much of the drug or xenobiotic can be found in various tissues and organs, and is influenced by factors such as blood flow, lipid solubility, protein binding, and the permeability of cell membranes. Understanding tissue distribution is important for predicting the potential effects of a drug or toxin on different parts of the body, and for designing drugs with improved safety and efficacy profiles.

Lead radioisotopes refer to specific types of radioactive isotopes (or radionuclides) of the element lead. These isotopes have unstable nuclei and emit radiation as they decay over time, changing into different elements in the process. Examples of lead radioisotopes include lead-210, lead-212, and lead-214. These isotopes are often found in the decay chains of heavier radioactive elements such as uranium and thorium, and they have various applications in fields like nuclear medicine, research, and industrial radiography. However, exposure to high levels of radiation from lead radioisotopes can pose significant health risks, including damage to DNA and increased risk of cancer.

Astatine is a naturally occurring, radioactive, semi-metallic chemical element with the symbol At and atomic number 85. It is the rarest naturally occurring element in the Earth's crust, and the heaviest of the halogens. Astatine is not found free in nature, but is always found in combination with other elements, such as uranium and thorium.

Astatine is a highly reactive element that exists in several allotropic forms and is characterized by its metallic appearance and chemical properties similar to those of iodine. It has a short half-life, ranging from a few hours to a few days, depending on the isotope, and emits alpha, beta, and gamma radiation.

Due to its rarity, radioactivity, and short half-life, astatine has limited practical applications. However, it has been studied for potential use in medical imaging and cancer therapy due to its ability to selectively accumulate in tumors.

Carcinoembryonic antigen (CEA) is a protein that is normally produced in small amounts during fetal development. In adults, low levels of CEA can be found in the blood, but elevated levels are typically associated with various types of cancer, particularly colon, rectal, and breast cancer.

Measurement of CEA levels in the blood is sometimes used as a tumor marker to monitor response to treatment, detect recurrence, or screen for secondary cancers in patients with a history of certain types of cancer. However, it's important to note that CEA is not a specific or sensitive indicator of cancer and can be elevated in various benign conditions such as inflammation, smoking, and some gastrointestinal diseases. Therefore, the test should be interpreted in conjunction with other clinical and diagnostic findings.

Pentetic Acid, also known as DTPA (Diethylenetriaminepentaacetic acid), is not a medication itself but a chelating agent used in the preparation of pharmaceutical products. A chelating agent is a compound that can form multiple bonds with metal ions, allowing them to be excreted from the body.

Pentetic Acid is used in medical treatments to remove or decrease the levels of certain toxic metals, such as lead, plutonium, americium, and curium, from the body. It can be given intravenously or orally, depending on the specific situation and the formulation of the medication.

It is important to note that the use of Pentetic Acid should be under the supervision of a healthcare professional, as it can also bind to essential metals like zinc, calcium, and iron, which can lead to deficiencies if not properly managed.

"Nude mice" is a term used in the field of laboratory research to describe a strain of mice that have been genetically engineered to lack a functional immune system. Specifically, nude mice lack a thymus gland and have a mutation in the FOXN1 gene, which results in a failure to develop a mature T-cell population. This means that they are unable to mount an effective immune response against foreign substances or organisms.

The name "nude" refers to the fact that these mice also have a lack of functional hair follicles, resulting in a hairless or partially hairless phenotype. This feature is actually a secondary consequence of the same genetic mutation that causes their immune deficiency.

Nude mice are commonly used in research because their weakened immune system makes them an ideal host for transplanted tumors, tissues, and cells from other species, including humans. This allows researchers to study the behavior of these foreign substances in a living organism without the complication of an immune response. However, it's important to note that because nude mice lack a functional immune system, they must be kept in sterile conditions and are more susceptible to infection than normal mice.

Radioimmunodetection (RID) is a medical diagnostic technique that combines the specificity of antibodies with the sensitivity of radioisotopes to detect and locate antigens or tumor markers within the body. This technique involves labeling antibodies with radioactive isotopes, which are then introduced into the patient's body. The labeled antibodies bind to the target antigens, allowing for their detection and localization using external gamma cameras.

The process typically begins with the production of monoclonal or polyclonal antibodies that specifically recognize and bind to a particular antigen associated with a disease or condition. These antibodies are then labeled with radioisotopes such as technetium-99m, iodine-131, or indium-111, which emit gamma rays that can be detected by external imaging devices.

Once the labeled antibodies have been administered to the patient, they circulate throughout the body and bind to their respective antigens. The bound radioactive antibodies can then be imaged using a gamma camera or single-photon emission computed tomography (SPECT) scanner, providing information about the location, size, and distribution of the target antigens within the body.

Radioimmunodetection has been widely used in the detection and monitoring of various malignancies, including cancerous tumors and metastases, as well as inflammatory and infectious diseases. It offers several advantages over other diagnostic techniques, such as high sensitivity, specificity, and non-invasiveness, making it an essential tool in modern medical imaging and diagnostics.

Actinium is a naturally occurring radioactive metallic element with the symbol Ac and atomic number 89. It was discovered in 1899 by André-Louis Debierne, a French chemist, who isolated it from uranium ore. Actinium is one of the actinides, a series of elements in the periodic table that are characterized by their radioactivity and their position in the f-block of the periodic table.

Actinium has no biological role in humans or other organisms, and exposure to its radiation can be harmful. It is not found in significant quantities in the environment, but it can be produced artificially through nuclear reactions. Actinium has a few potential medical applications, including as a component of radioactive compounds used for cancer treatment. However, its use in medicine is limited due to its radioactivity and toxicity.

Non-Hodgkin lymphoma (NHL) is a type of cancer that originates in the lymphatic system, which is part of the immune system. It involves the abnormal growth and proliferation of malignant lymphocytes (a type of white blood cell), leading to the formation of tumors in lymph nodes, spleen, bone marrow, or other organs. NHL can be further classified into various subtypes based on the specific type of lymphocyte involved and its characteristics.

The symptoms of Non-Hodgkin lymphoma may include:

* Painless swelling of lymph nodes in the neck, armpits, or groin
* Persistent fatigue
* Unexplained weight loss
* Fever
* Night sweats
* Itchy skin

The exact cause of Non-Hodgkin lymphoma is not well understood, but it has been associated with certain risk factors such as age (most common in people over 60), exposure to certain chemicals, immune system deficiencies, and infection with viruses like Epstein-Barr virus or HIV.

Treatment for Non-Hodgkin lymphoma depends on the stage and subtype of the disease, as well as the patient's overall health. Treatment options may include chemotherapy, radiation therapy, immunotherapy, targeted therapy, stem cell transplantation, or a combination of these approaches. Regular follow-up care is essential to monitor the progression of the disease and manage any potential long-term side effects of treatment.

Streptavidin is not a medical term per se, but rather a biochemical term used in the field of medicine and laboratory research. Streptavidin is a protein that is derived from the bacterium Streptomyces avidinii. It has a unique ability to bind very strongly and specifically to another molecule called biotin, with an association constant that is one of the strongest non-covalent interactions known in nature.

This property makes streptavidin a valuable tool in various medical and research applications such as immunoassays, histology, molecular biology, and drug delivery systems. For example, biotinylated molecules (such as antibodies, DNA, or enzymes) can be linked to streptavidin for detection, purification, or targeting purposes.

In summary, streptavidin is a bacterial protein that binds strongly and specifically to biotin, which is used in various medical and research applications as a tool for detection, purification, or targeting purposes.

Bispecific antibodies are a type of artificial protein that have been engineered to recognize and bind to two different antigens simultaneously. They are created by combining two separate antibody molecules, each with a unique binding site, into a single entity. This allows the bispecific antibody to link two cells or proteins together, bringing them into close proximity and facilitating various biological processes.

In the context of medicine and immunotherapy, bispecific antibodies are being investigated as a potential treatment for cancer and other diseases. For example, a bispecific antibody can be designed to recognize a specific tumor-associated antigen on the surface of cancer cells, while also binding to a component of the immune system, such as a T cell. This brings the T cell into close contact with the cancer cell, activating the immune system and triggering an immune response against the tumor.

Bispecific antibodies have several potential advantages over traditional monoclonal antibodies, which only recognize a single antigen. By targeting two different epitopes or antigens, bispecific antibodies can increase the specificity and affinity of the interaction, reducing off-target effects and improving therapeutic efficacy. Additionally, bispecific antibodies can bring together multiple components of the immune system, amplifying the immune response and enhancing the destruction of cancer cells.

Overall, bispecific antibodies represent a promising new class of therapeutics that have the potential to revolutionize the treatment of cancer and other diseases. However, further research is needed to fully understand their mechanisms of action and optimize their clinical use.

Immunoconjugates are biomolecules created by the conjugation (coupling) of an antibody or antibody fragment with a cytotoxic agent, such as a drug, radionuclide, or toxin. This coupling is designed to direct the cytotoxic agent specifically to target cells, usually cancer cells, against which the antibody is directed, thereby increasing the effectiveness and reducing the side effects of the therapy.

The antibody part of the immunoconjugate recognizes and binds to specific antigens (proteins or other molecules) on the surface of the target cells, while the cytotoxic agent part enters the cell and disrupts its function, leading to cell death. The linker between the two parts is designed to be stable in circulation but can release the cytotoxic agent once inside the target cell.

Immunoconjugates are a promising area of research in targeted cancer therapy, as they offer the potential for more precise and less toxic treatments compared to traditional chemotherapy. However, their development and use also pose challenges, such as ensuring that the immunoconjugate binds specifically to the target cells and not to normal cells, optimizing the dose and schedule of treatment, and minimizing the risk of resistance to the therapy.

Radiopharmaceuticals are defined as pharmaceutical preparations that contain radioactive isotopes and are used for diagnosis or therapy in nuclear medicine. These compounds are designed to interact specifically with certain biological targets, such as cells, tissues, or organs, and emit radiation that can be detected and measured to provide diagnostic information or used to destroy abnormal cells or tissue in therapeutic applications.

The radioactive isotopes used in radiopharmaceuticals have carefully controlled half-lives, which determine how long they remain radioactive and how long the pharmaceutical preparation remains effective. The choice of radioisotope depends on the intended use of the radiopharmaceutical, as well as factors such as its energy, range of emission, and chemical properties.

Radiopharmaceuticals are used in a wide range of medical applications, including imaging, cancer therapy, and treatment of other diseases and conditions. Examples of radiopharmaceuticals include technetium-99m for imaging the heart, lungs, and bones; iodine-131 for treating thyroid cancer; and samarium-153 for palliative treatment of bone metastases.

The use of radiopharmaceuticals requires specialized training and expertise in nuclear medicine, as well as strict adherence to safety protocols to minimize radiation exposure to patients and healthcare workers.

Neoplasm transplantation is not a recognized or established medical procedure in the field of oncology. The term "neoplasm" refers to an abnormal growth of cells, which can be benign or malignant (cancerous). "Transplantation" typically refers to the surgical transfer of living cells, tissues, or organs from one part of the body to another or between individuals.

The concept of neoplasm transplantation may imply the transfer of cancerous cells or tissues from a donor to a recipient, which is not a standard practice due to ethical considerations and the potential harm it could cause to the recipient. In some rare instances, researchers might use laboratory animals to study the transmission and growth of human cancer cells, but this is done for scientific research purposes only and under strict regulatory guidelines.

In summary, there is no medical definition for 'Neoplasm Transplantation' as it does not represent a standard or ethical medical practice.

Immunotoxins are biomolecules that combine the specificity of an antibody with the toxicity of a toxin. They are created by chemically linking a monoclonal antibody (that recognizes and binds to a specific cell surface antigen) to a protein toxin (that inhibits protein synthesis in cells). The immunotoxin selectively binds to the target cell, gets internalized, and releases the toxin into the cytosol, leading to cell death. Immunotoxins have been explored as potential therapeutic agents for targeted cancer therapy and treatment of other diseases.

I'm sorry for any confusion, but "Ytterbium" is not a medical term. It is a chemical element with the symbol "Yb" and atomic number 70. Ytterbium is a rare earth metal that is silvery white, soft, malleable, and has many uses in scientific research, particularly in the field of laser technology.

If you have any medical questions or terms you would like me to define, please let me know!

Copper radioisotopes are radioactive isotopes or variants of the chemical element copper. These isotopes have an unstable nucleus and emit radiation as they decay over time. Copper has several radioisotopes, including copper-64, copper-67, and copper-60, among others. These radioisotopes are used in various medical applications such as diagnostic imaging, therapy, and research. For example, copper-64 is used in positron emission tomography (PET) scans to help diagnose diseases like cancer, while copper-67 is used in targeted radionuclide therapy for cancer treatment. The use of radioisotopes in medicine requires careful handling and regulation due to their radiation hazards.

A dose-response relationship in radiation refers to the correlation between the amount of radiation exposure (dose) and the biological response or adverse health effects observed in exposed individuals. As the level of radiation dose increases, the severity and frequency of the adverse health effects also tend to increase. This relationship is crucial in understanding the risks associated with various levels of radiation exposure and helps inform radiation protection standards and guidelines.

The effects of ionizing radiation can be categorized into two types: deterministic and stochastic. Deterministic effects have a threshold dose below which no effect is observed, and above this threshold, the severity of the effect increases with higher doses. Examples include radiation-induced cataracts or radiation dermatitis. Stochastic effects, on the other hand, do not have a clear threshold and are based on probability; as the dose increases, so does the likelihood of the adverse health effect occurring, such as an increased risk of cancer.

Understanding the dose-response relationship in radiation exposure is essential for setting limits on occupational and public exposure to ionizing radiation, optimizing radiation protection practices, and developing effective medical countermeasures in case of radiation emergencies.

B-cell lymphoma is a type of cancer that originates from the B-lymphocytes, which are a part of the immune system and play a crucial role in fighting infections. These cells can develop mutations in their DNA, leading to uncontrolled growth and division, resulting in the formation of a tumor.

B-cell lymphomas can be classified into two main categories: Hodgkin's lymphoma and non-Hodgkin's lymphoma. B-cell lymphomas are further divided into subtypes based on their specific characteristics, such as the appearance of the cells under a microscope, the genetic changes present in the cancer cells, and the aggressiveness of the disease.

Some common types of B-cell lymphomas include diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and Burkitt lymphoma. Treatment options for B-cell lymphomas depend on the specific subtype, stage of the disease, and other individual factors. Treatment may include chemotherapy, radiation therapy, immunotherapy, targeted therapy, or stem cell transplantation.

Heterologous transplantation is a type of transplantation where an organ or tissue is transferred from one species to another. This is in contrast to allogeneic transplantation, where the donor and recipient are of the same species, or autologous transplantation, where the donor and recipient are the same individual.

In heterologous transplantation, the immune systems of the donor and recipient are significantly different, which can lead to a strong immune response against the transplanted organ or tissue. This is known as a graft-versus-host disease (GVHD), where the immune cells in the transplanted tissue attack the recipient's body.

Heterologous transplantation is not commonly performed in clinical medicine due to the high risk of rejection and GVHD. However, it may be used in research settings to study the biology of transplantation and to develop new therapies for transplant rejection.

Hematology is a branch of medicine that deals with the study of blood, its physiology, and pathophysiology. It involves the diagnosis, treatment, and prevention of diseases related to the blood and blood-forming organs such as the bone marrow, spleen, and lymphatic system. This includes disorders of red and white blood cells, platelets, hemoglobin, blood vessels, and coagulation (blood clotting). Some common hematological diseases include anemia, leukemia, lymphoma, sickle cell disease, and bleeding disorders like hemophilia.

'Antibodies, Neoplasm' is a medical term that refers to abnormal antibodies produced by neoplastic cells, which are cells that have undergone uncontrolled division and form a tumor or malignancy. These antibodies can be produced in large quantities and may have altered structures or functions compared to normal antibodies.

Neoplastic antibodies can arise from various types of malignancies, including leukemias, lymphomas, and multiple myeloma. In some cases, these abnormal antibodies can interfere with the normal functioning of the immune system and contribute to the progression of the disease.

In addition, neoplastic antibodies can also be used as tumor markers for diagnostic purposes. For example, certain types of monoclonal gammopathy, such as multiple myeloma, are characterized by the overproduction of a single type of immunoglobulin, which can be detected in the blood or urine and used to monitor the disease.

Overall, 'Antibodies, Neoplasm' is a term that encompasses a wide range of abnormal antibodies produced by neoplastic cells, which can have significant implications for both the diagnosis and treatment of malignancies.

Neptunium is not a medical term, but a chemical element in the periodic table with the symbol Np and atomic number 93. It is a synthetic actinide metal that does not naturally occur on Earth, but was first produced by artificial means in 1940.

Neptunium has no known biological role and is not essential to living organisms. However, it can be harmful to human health if ingested or inhaled due to its radioactive properties. Exposure to neptunium can increase the risk of cancer and other diseases. Therefore, handling and disposal of neptunium and its compounds require strict safety measures and regulations.

Siglec-2, also known as CD22, is a type of cell surface protein that belongs to the sialic acid-binding immunoglobulin-like lectins (Siglecs) family. It is primarily expressed on mature B cells and plays a crucial role in regulating B cell activation and function. Siglec-2 recognizes and binds to sialic acid residues on glycoproteins and gangliosides, which are sugars that are attached to proteins and lipids on the surface of cells. This binding can lead to inhibitory signals that dampen B cell activation and help prevent autoimmunity. Siglec-2 has also been implicated in the regulation of B cell migration and adhesion.

Radiation dosage, in the context of medical physics, refers to the amount of radiation energy that is absorbed by a material or tissue, usually measured in units of Gray (Gy), where 1 Gy equals an absorption of 1 Joule of radiation energy per kilogram of matter. In the clinical setting, radiation dosage is used to plan and assess the amount of radiation delivered to a patient during treatments such as radiotherapy. It's important to note that the biological impact of radiation also depends on other factors, including the type and energy level of the radiation, as well as the sensitivity of the irradiated tissues or organs.

Isotope labeling is a scientific technique used in the field of medicine, particularly in molecular biology, chemistry, and pharmacology. It involves replacing one or more atoms in a molecule with a radioactive or stable isotope of the same element. This modified molecule can then be traced and analyzed to study its structure, function, metabolism, or interaction with other molecules within biological systems.

Radioisotope labeling uses unstable radioactive isotopes that emit radiation, allowing for detection and quantification of the labeled molecule using various imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT). This approach is particularly useful in tracking the distribution and metabolism of drugs, hormones, or other biomolecules in living organisms.

Stable isotope labeling, on the other hand, employs non-radioactive isotopes that do not emit radiation. These isotopes have different atomic masses compared to their natural counterparts and can be detected using mass spectrometry. Stable isotope labeling is often used in metabolic studies, protein turnover analysis, or for identifying the origin of specific molecules within complex biological samples.

In summary, isotope labeling is a versatile tool in medical research that enables researchers to investigate various aspects of molecular behavior and interactions within biological systems.

Biotin is a water-soluble vitamin, also known as Vitamin B7 or Vitamin H. It is a cofactor for several enzymes involved in metabolism, particularly in the synthesis and breakdown of fatty acids, amino acids, and carbohydrates. Biotin plays a crucial role in maintaining healthy skin, hair, nails, nerves, and liver function. It is found in various foods such as nuts, seeds, whole grains, milk, and vegetables. Biotin deficiency is rare but can occur in people with malnutrition, alcoholism, pregnancy, or certain genetic disorders.

Combined modality therapy (CMT) is a medical treatment approach that utilizes more than one method or type of therapy simultaneously or in close succession, with the goal of enhancing the overall effectiveness of the treatment. In the context of cancer care, CMT often refers to the combination of two or more primary treatment modalities, such as surgery, radiation therapy, and systemic therapies (chemotherapy, immunotherapy, targeted therapy, etc.).

The rationale behind using combined modality therapy is that each treatment method can target cancer cells in different ways, potentially increasing the likelihood of eliminating all cancer cells and reducing the risk of recurrence. The specific combination and sequence of treatments will depend on various factors, including the type and stage of cancer, patient's overall health, and individual preferences.

For example, a common CMT approach for locally advanced rectal cancer may involve preoperative (neoadjuvant) chemoradiation therapy, followed by surgery to remove the tumor, and then postoperative (adjuvant) chemotherapy. This combined approach allows for the reduction of the tumor size before surgery, increases the likelihood of complete tumor removal, and targets any remaining microscopic cancer cells with systemic chemotherapy.

It is essential to consult with a multidisciplinary team of healthcare professionals to determine the most appropriate CMT plan for each individual patient, considering both the potential benefits and risks associated with each treatment method.

Beta particles, also known as beta rays, are a type of ionizing radiation that consist of high-energy electrons or positrons emitted from the nucleus of certain radioactive isotopes during their decay process. When a neutron in the nucleus decays into a proton, it results in an excess energy state and one electron is ejected from the atom at high speed. This ejected electron is referred to as a beta particle.

Beta particles can have both positive and negative charges, depending on the type of decay process. Negative beta particles (β−) are equivalent to electrons, while positive beta particles (β+) are equivalent to positrons. They possess kinetic energy that varies in range, with higher energies associated with greater penetrating power.

Beta particles can cause ionization and excitation of atoms and molecules they encounter, leading to chemical reactions and potential damage to living tissues. Therefore, appropriate safety measures must be taken when handling materials that emit beta radiation.

Organometallic compounds are a type of chemical compound that contain at least one metal-carbon bond. This means that the metal is directly attached to carbon atom(s) from an organic molecule. These compounds can be synthesized through various methods, and they have found widespread use in industrial and medicinal applications, including catalysis, polymerization, and pharmaceuticals.

It's worth noting that while organometallic compounds contain metal-carbon bonds, not all compounds with metal-carbon bonds are considered organometallic. For example, in classical inorganic chemistry, simple salts of metal carbonyls (M(CO)n) are not typically classified as organometallic, but rather as metal carbonyl complexes. The distinction between these classes of compounds can sometimes be subtle and is a matter of ongoing debate among chemists.

Avidin is a protein found in the white of eggs (egg whites) and some other animal tissues. It has a high binding affinity for biotin, also known as vitamin B7 or vitamin H, which is an essential nutrient for humans and other organisms. This property makes avidin useful in various biochemical and medical applications, such as immunohistochemistry, blotting techniques, and drug delivery systems.

Biotin-avidin interactions are among the strongest non-covalent interactions known in nature, with a dissociation constant (Kd) of approximately 10^-15 M. This means that once biotin is bound to avidin, it is very difficult to separate them. In some cases, this property can be exploited to create stable and specific complexes for various applications.

However, it's worth noting that the high affinity of avidin for biotin can also have negative effects in certain contexts. For example, raw egg whites contain large amounts of avidin, which can bind to biotin in the gut and prevent its absorption if consumed in sufficient quantities. This can lead to biotin deficiency, which can cause various health problems. Cooking egg whites denatures avidin and reduces its ability to bind to biotin, making cooked eggs a safe source of biotin.

Heterocyclic compounds are organic compounds that contain at least one atom within the ring structure, other than carbon, such as nitrogen, oxygen, sulfur or phosphorus. These compounds make up a large class of naturally occurring and synthetic materials, including many drugs, pigments, vitamins, and antibiotics. The presence of the heteroatom in the ring can have significant effects on the physical and chemical properties of the compound, such as its reactivity, stability, and bonding characteristics. Examples of heterocyclic compounds include pyridine, pyrimidine, and furan.

A xenograft model antitumor assay is a type of preclinical cancer research study that involves transplanting human tumor cells or tissues into an immunodeficient mouse. This model allows researchers to study the effects of various treatments, such as drugs or immune therapies, on human tumors in a living organism.

In this assay, human tumor cells or tissues are implanted into the mouse, typically under the skin or in another organ, where they grow and form a tumor. Once the tumor has established, the mouse is treated with the experimental therapy, and the tumor's growth is monitored over time. The response of the tumor to the treatment is then assessed by measuring changes in tumor size or weight, as well as other parameters such as survival rate and metastasis.

Xenograft model antitumor assays are useful for evaluating the efficacy and safety of new cancer therapies before they are tested in human clinical trials. They provide valuable information on how the tumors respond to treatment, drug pharmacokinetics, and toxicity, which can help researchers optimize dosing regimens and identify potential side effects. However, it is important to note that xenograft models have limitations, such as differences in tumor biology between mice and humans, and may not always predict how well a therapy will work in human patients.

Monoclonal murine-derived antibodies are a type of laboratory-produced antibody that is identical in structure, having been derived from a single clone of cells. These antibodies are created using mouse cells and are therefore composed entirely of mouse immune proteins. They are designed to bind specifically to a particular target protein or antigen, making them useful tools for research, diagnostic testing, and therapeutic applications.

Monoclonal antibodies offer several advantages over polyclonal antibodies (which are derived from multiple clones of cells and can recognize multiple epitopes on an antigen). Monoclonal antibodies have a consistent and uniform structure, making them more reliable for research and diagnostic purposes. They also have higher specificity and affinity for their target antigens, allowing for more sensitive detection and measurement.

However, there are some limitations to using monoclonal murine-derived antibodies in therapeutic applications. Because they are composed entirely of mouse proteins, they can elicit an immune response in humans, leading to the production of human anti-mouse antibodies (HAMA) that can neutralize their effectiveness. To overcome this limitation, researchers have developed chimeric and humanized monoclonal antibodies that incorporate human protein sequences, reducing the risk of an immune response.

Follicular lymphoma is a specific type of low-grade or indolent non-Hodgkin lymphoma (NHL). It develops from the B-lymphocytes, a type of white blood cell found in the lymphatic system. This lymphoma is characterized by the presence of abnormal follicles or nodules in the lymph nodes and other organs. The neoplastic cells in this subtype exhibit a distinct growth pattern that resembles normal follicular centers, hence the name "follicular lymphoma."

The majority of cases involve a translocation between chromosomes 14 and 18 [t(14;18)], leading to an overexpression of the BCL-2 gene. This genetic alteration contributes to the cancer cells' resistance to programmed cell death, allowing them to accumulate in the body.

Follicular lymphoma is typically slow-growing and may not cause symptoms for a long time. Common manifestations include painless swelling of lymph nodes, fatigue, weight loss, and night sweats. Treatment options depend on various factors such as the stage of the disease, patient's age, and overall health. Watchful waiting, chemotherapy, immunotherapy, targeted therapy, radiation therapy, or a combination of these approaches may be used to manage follicular lymphoma.

Bone marrow is the spongy tissue found inside certain bones in the body, such as the hips, thighs, and vertebrae. It is responsible for producing blood-forming cells, including red blood cells, white blood cells, and platelets. There are two types of bone marrow: red marrow, which is involved in blood cell production, and yellow marrow, which contains fatty tissue.

Red bone marrow contains hematopoietic stem cells, which can differentiate into various types of blood cells. These stem cells continuously divide and mature to produce new blood cells that are released into the circulation. Red blood cells carry oxygen throughout the body, white blood cells help fight infections, and platelets play a crucial role in blood clotting.

Bone marrow also serves as a site for immune cell development and maturation. It contains various types of immune cells, such as lymphocytes, macrophages, and dendritic cells, which help protect the body against infections and diseases.

Abnormalities in bone marrow function can lead to several medical conditions, including anemia, leukopenia, thrombocytopenia, and various types of cancer, such as leukemia and multiple myeloma. Bone marrow aspiration and biopsy are common diagnostic procedures used to evaluate bone marrow health and function.

Colonic neoplasms refer to abnormal growths in the large intestine, also known as the colon. These growths can be benign (non-cancerous) or malignant (cancerous). The two most common types of colonic neoplasms are adenomas and carcinomas.

Adenomas are benign tumors that can develop into cancer over time if left untreated. They are often found during routine colonoscopies and can be removed during the procedure.

Carcinomas, on the other hand, are malignant tumors that invade surrounding tissues and can spread to other parts of the body. Colorectal cancer is the third leading cause of cancer-related deaths in the United States, and colonic neoplasms are a significant risk factor for developing this type of cancer.

Regular screenings for colonic neoplasms are recommended for individuals over the age of 50 or those with a family history of colorectal cancer or other risk factors. Early detection and removal of colonic neoplasms can significantly reduce the risk of developing colorectal cancer.

Immunoglobulin fragments refer to the smaller protein units that are formed by the digestion or break-down of an intact immunoglobulin, also known as an antibody. Immunoglobulins are large Y-shaped proteins produced by the immune system to identify and neutralize foreign substances such as pathogens or toxins. They consist of two heavy chains and two light chains, held together by disulfide bonds.

The digestion or break-down of an immunoglobulin can occur through enzymatic cleavage, which results in the formation of distinct fragments. The most common immunoglobulin fragments are:

1. Fab (Fragment, antigen binding) fragments: These are formed by the digestion of an intact immunoglobulin using the enzyme papain. Each Fab fragment contains a single antigen-binding site, consisting of a portion of one heavy chain and one light chain. The Fab fragments retain their ability to bind to specific antigens.
2. Fc (Fragment, crystallizable) fragments: These are formed by the digestion of an intact immunoglobulin using the enzyme pepsin or through the natural breakdown process in the body. The Fc fragment contains the constant region of both heavy chains and is responsible for effector functions such as complement activation, binding to Fc receptors on immune cells, and antibody-dependent cellular cytotoxicity (ADCC).

These immunoglobulin fragments play crucial roles in various immune responses and diagnostic applications. For example, Fab fragments can be used in immunoassays for the detection of specific antigens, while Fc fragments can mediate effector functions that help eliminate pathogens or damaged cells from the body.

Whole-body counting is a non-invasive nuclear medicine technique used for the detection and measurement of radioactivity in the human body. It involves the use of sensitive radiation detectors that can measure the gamma rays emitted by radionuclides present within the body tissues.

The individual lies on a table or sits in a chair with their entire body inside a large detector, which is typically a scintillation camera or a NaI(Tl) crystal. The detector measures the number and energy of gamma rays emitted from the body, allowing for the identification and quantification of specific radionuclides present within the body.

Whole-body counting has several clinical applications, including monitoring patients who have received therapeutic radioisotopes, evaluating the effectiveness of radiation therapy, detecting and measuring internal contamination due to accidental exposure or intentional intake, and assessing the distribution and retention of radionuclides in research studies.

It is important to note that whole-body counting does not provide anatomical information like other imaging techniques (e.g., CT, MRI), but rather offers functional data on the presence and quantity of radioactivity within the body.

Nuclear medicine is a branch of medical imaging that uses small amounts of radioactive material, called radiopharmaceuticals, to diagnose and treat various diseases. The radiopharmaceuticals are taken internally, usually through injection or oral administration, and accumulate in specific organs or tissues. A special camera then detects the radiation emitted by these substances, which helps create detailed images of the body's internal structures and functions.

The images produced in nuclear medicine can help doctors identify abnormalities such as tumors, fractures, infection, or inflammation. Additionally, some radiopharmaceuticals can be used to treat certain conditions, like hyperthyroidism or cancer, by delivering targeted doses of radiation directly to the affected area. Overall, nuclear medicine provides valuable information for the diagnosis, treatment planning, and monitoring of many medical conditions.

Immunoglobulin (Ig) Fab fragments are the antigen-binding portions of an antibody that result from the digestion of the whole antibody molecule by enzymes such as papain. An antibody, also known as an immunoglobulin, is a Y-shaped protein produced by the immune system to identify and neutralize foreign substances like bacteria, viruses, or toxins. The antibody has two identical antigen-binding sites, located at the tips of the two shorter arms, which can bind specifically to a target antigen.

Fab fragments are formed when an antibody is cleaved by papain, resulting in two Fab fragments and one Fc fragment. Each Fab fragment contains one antigen-binding site, composed of a variable region (Fv) and a constant region (C). The Fv region is responsible for the specificity and affinity of the antigen binding, while the C region contributes to the effector functions of the antibody.

Fab fragments are often used in various medical applications, such as immunodiagnostics and targeted therapies, due to their ability to bind specifically to target antigens without triggering an immune response or other effector functions associated with the Fc region.

Radionuclide generators, also known as "radiogenic sources" or "generator systems," are devices that contain a parent radionuclide that decays into a daughter radionuclide. The parent nuclide has a longer half-life than the daughter nuclide and remains within the generator system, while the daughter nuclide is produced continuously through the decay process and can be extracted for use in medical imaging or therapeutic procedures.

The most common type of radionuclide generator used in nuclear medicine is the technetium-99m (^99m Tc) generator, which contains molybdenum-99 (^99 Mo) as the parent nuclide. Molybdenum-99 has a half-life of 66 hours and decays into technetium-99m, which has a half-life of only 6 hours. Technetium-99m emits gamma rays that can be detected by gamma cameras, making it useful for a wide range of diagnostic procedures such as bone scans, lung perfusion imaging, and myocardial perfusion imaging.

Radionuclide generators are typically used in hospitals and medical centers where they can provide a convenient and cost-effective way to produce small quantities of radionuclides for diagnostic or therapeutic purposes. The extracted daughter nuclide can be used immediately, reducing the need for complex shipping and handling procedures associated with other radioactive materials.

"Medicine in Art" is not a medical term per se, but rather a term used to describe the intersection and representation of medical themes, practices, or symbols in various art forms. It can include but is not limited to:

1. The depiction of medical scenes, practitioners, or patients in paintings, sculptures, or photographs.
2. The use of medical imagery such as X-rays, MRIs, or anatomical drawings in mixed media works.
3. The exploration of medical issues, diseases, or treatments in conceptual art.
4. The creation of art by artists with medical conditions, which can provide insight into their experiences.
5. The use of art therapy as a healing modality in medical settings.

This term is often used in the context of art history, visual culture, and medical humanities to analyze and understand the complex relationships between art, medicine, and society.

Tetrahydrouridine (THU) is not a medication itself, but rather a metabolic inhibitor. It is a derivative of the nucleoside uridine and has been studied in the context of its ability to inhibit the enzyme cytidine deaminase. This enzyme is responsible for the breakdown of certain antiviral medications, such as zidovudine (AZT) and stavudine (d4T), which are used in the treatment of HIV infection.

By inhibiting cytidine deaminase, THU can help to increase the levels and effectiveness of these antiviral drugs, while also reducing some of their side effects. However, it is important to note that THU is not currently approved for use as a medication by itself and is typically used in research or experimental settings in combination with other antiretroviral therapies.

Relative Biological Effectiveness (RBE) is a term used in radiation biology and medicine to describe the relative effectiveness of different types or energies of ionizing radiation in causing biological damage, compared to a reference radiation such as high-energy photons (X-rays or gamma rays). RBE takes into account the differences in biological impact between various types of radiation, which can be due to differences in linear energy transfer (LET), quality factor, and other factors. It is used to estimate the biological effects of mixed radiation fields, such as those encountered in radiotherapy treatments that combine different types or energies of radiation. The RBE value for a specific type of radiation is determined through experimental studies that compare its biological impact to that of the reference radiation.

A cell line that is derived from tumor cells and has been adapted to grow in culture. These cell lines are often used in research to study the characteristics of cancer cells, including their growth patterns, genetic changes, and responses to various treatments. They can be established from many different types of tumors, such as carcinomas, sarcomas, and leukemias. Once established, these cell lines can be grown and maintained indefinitely in the laboratory, allowing researchers to conduct experiments and studies that would not be feasible using primary tumor cells. It is important to note that tumor cell lines may not always accurately represent the behavior of the original tumor, as they can undergo genetic changes during their time in culture.

Monoclonal antibodies are laboratory-produced proteins that mimic the immune system's ability to fight off harmful antigens such as viruses and cancer cells. They are created by fusing a single B cell (the type of white blood cell responsible for producing antibodies) with a tumor cell, resulting in a hybrid cell called a hybridoma. This hybridoma can then be cloned to produce a large number of identical cells, all producing the same antibody, hence "monoclonal."

Humanized monoclonal antibodies are a type of monoclonal antibody that have been genetically engineered to include human components. This is done to reduce the risk of an adverse immune response in patients receiving the treatment. In this process, the variable region of the mouse monoclonal antibody, which contains the antigen-binding site, is grafted onto a human constant region. The resulting humanized monoclonal antibody retains the ability to bind to the target antigen while minimizing the immunogenicity associated with murine (mouse) antibodies.

In summary, "antibodies, monoclonal, humanized" refers to a type of laboratory-produced protein that mimics the immune system's ability to fight off harmful antigens, but with reduced immunogenicity due to the inclusion of human components in their structure.

Treatment outcome is a term used to describe the result or effect of medical treatment on a patient's health status. It can be measured in various ways, such as through symptoms improvement, disease remission, reduced disability, improved quality of life, or survival rates. The treatment outcome helps healthcare providers evaluate the effectiveness of a particular treatment plan and make informed decisions about future care. It is also used in clinical research to compare the efficacy of different treatments and improve patient care.

Peritoneal neoplasms refer to tumors or cancerous growths that develop in the peritoneum, which is the thin, transparent membrane that lines the inner wall of the abdomen and covers the organs within it. These neoplasms can be benign (non-cancerous) or malignant (cancerous). Malignant peritoneal neoplasms are often associated with advanced stages of gastrointestinal, ovarian, or uterine cancers and can spread (metastasize) to other parts of the abdomen.

Peritoneal neoplasms can cause various symptoms such as abdominal pain, bloating, nausea, vomiting, loss of appetite, and weight loss. Diagnosis typically involves imaging tests like CT scans or MRIs, followed by a biopsy to confirm the presence of cancerous cells. Treatment options may include surgery, chemotherapy, radiation therapy, or a combination of these approaches, depending on the type, stage, and location of the neoplasm.

Expert testimony is a type of evidence presented in court by a qualified expert who has specialized knowledge, education, training, or experience in a particular field that is relevant to the case. The expert's role is to provide an objective and unbiased opinion based on their expertise to assist the judge or jury in understanding complex issues that are beyond the knowledge of the average person.

In medical cases, expert testimony may be presented by healthcare professionals such as doctors, nurses, or other medical experts who have specialized knowledge about the medical condition or treatment at issue. The expert's testimony can help establish the standard of care, diagnose a medical condition, evaluate the cause of an injury, or assess the damages suffered by the plaintiff.

Expert testimony must meet certain legal standards to be admissible in court. The expert must be qualified to testify based on their education, training, and experience, and their opinion must be based on reliable methods and data. Additionally, the expert's testimony must be relevant to the case and not unduly prejudicial or misleading.

Overall, expert testimony plays a critical role in medical cases by providing objective and unbiased evidence that can help judges and juries make informed decisions about complex medical issues.

Lymphoma is a type of cancer that originates from the white blood cells called lymphocytes, which are part of the immune system. These cells are found in various parts of the body such as the lymph nodes, spleen, bone marrow, and other organs. Lymphoma can be classified into two main types: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).

HL is characterized by the presence of a specific type of abnormal lymphocyte called Reed-Sternberg cells, while NHL includes a diverse group of lymphomas that lack these cells. The symptoms of lymphoma may include swollen lymph nodes, fever, night sweats, weight loss, and fatigue.

The exact cause of lymphoma is not known, but it is believed to result from genetic mutations in the lymphocytes that lead to uncontrolled cell growth and division. Exposure to certain viruses, chemicals, and radiation may increase the risk of developing lymphoma. Treatment options for lymphoma depend on various factors such as the type and stage of the disease, age, and overall health of the patient. Common treatments include chemotherapy, radiation therapy, immunotherapy, and stem cell transplantation.

Computer-assisted radiotherapy planning (CARP) is the use of computer systems and software to assist in the process of creating a treatment plan for radiotherapy. The goal of radiotherapy is to deliver a precise and effective dose of radiation to a tumor while minimizing exposure to healthy tissue. CARP involves using imaging data, such as CT or MRI scans, to create a 3D model of the patient's anatomy. This model is then used to simulate the delivery of radiation from different angles and determine the optimal treatment plan. The use of computers in this process allows for more accurate and efficient planning, as well as the ability to easily adjust the plan as needed.

BALB/c is an inbred strain of laboratory mouse that is widely used in biomedical research. The strain was developed at the Institute of Cancer Research in London by Henry Baldwin and his colleagues in the 1920s, and it has since become one of the most commonly used inbred strains in the world.

BALB/c mice are characterized by their black coat color, which is determined by a recessive allele at the tyrosinase locus. They are also known for their docile and friendly temperament, making them easy to handle and work with in the laboratory.

One of the key features of BALB/c mice that makes them useful for research is their susceptibility to certain types of tumors and immune responses. For example, they are highly susceptible to developing mammary tumors, which can be induced by chemical carcinogens or viral infection. They also have a strong Th2-biased immune response, which makes them useful models for studying allergic diseases and asthma.

BALB/c mice are also commonly used in studies of genetics, neuroscience, behavior, and infectious diseases. Because they are an inbred strain, they have a uniform genetic background, which makes it easier to control for genetic factors in experiments. Additionally, because they have been bred in the laboratory for many generations, they are highly standardized and reproducible, making them ideal subjects for scientific research.

Experimental neoplasms refer to abnormal growths or tumors that are induced and studied in a controlled laboratory setting, typically in animals or cell cultures. These studies are conducted to understand the fundamental mechanisms of cancer development, progression, and potential treatment strategies. By manipulating various factors such as genetic mutations, environmental exposures, and pharmacological interventions, researchers can gain valuable insights into the complex processes underlying neoplasm formation and identify novel targets for cancer therapy. It is important to note that experimental neoplasms may not always accurately represent human cancers, and further research is needed to translate these findings into clinically relevant applications.

"Body burden" is a term used in the field of environmental health to describe the total amount of a chemical or toxic substance that an individual has accumulated in their body tissues and fluids. It refers to the overall load or concentration of a particular chemical or contaminant that an organism is carrying, which can come from various sources such as air, water, food, and consumer products.

The term "body burden" highlights the idea that people can be exposed to harmful substances unknowingly and unintentionally, leading to potential health risks over time. Some factors that may influence body burden include the frequency and duration of exposure, the toxicity of the substance, and individual differences in metabolism, elimination, and susceptibility.

It is important to note that not all chemicals or substances found in the body are necessarily harmful, as some are essential for normal bodily functions. However, high levels of certain environmental contaminants can have adverse health effects, making it crucial to monitor and regulate exposure to these substances.

Radiation-sensitizing agents are drugs that make cancer cells more sensitive to radiation therapy. These agents work by increasing the ability of radiation to damage the DNA of cancer cells, which can lead to more effective tumor cell death. This means that lower doses of radiation may be required to achieve the same therapeutic effect, reducing the potential for damage to normal tissues surrounding the tumor.

Radiation-sensitizing agents are often used in conjunction with radiation therapy to improve treatment outcomes for patients with various types of cancer. They can be given either systemically (through the bloodstream) or locally (directly to the tumor site). The choice of agent and the timing of administration depend on several factors, including the type and stage of cancer, the patient's overall health, and the specific radiation therapy protocol being used.

It is important to note that while radiation-sensitizing agents can enhance the effectiveness of radiation therapy, they may also increase the risk of side effects. Therefore, careful monitoring and management of potential toxicities are essential during treatment.

Medullary carcinoma is a type of cancer that develops in the neuroendocrine cells of the thyroid gland. These cells produce hormones that help regulate various bodily functions. Medullary carcinoma is a relatively rare form of thyroid cancer, accounting for about 5-10% of all cases.

Medullary carcinoma is characterized by the presence of certain genetic mutations that cause the overproduction of calcitonin, a hormone produced by the neuroendocrine cells. This overproduction can lead to the formation of tumors in the thyroid gland.

Medullary carcinoma can be hereditary or sporadic. Hereditary forms of the disease are caused by mutations in the RET gene and are often associated with multiple endocrine neoplasia type 2 (MEN 2), a genetic disorder that affects the thyroid gland, adrenal glands, and parathyroid glands. Sporadic forms of medullary carcinoma, on the other hand, are not inherited and occur randomly in people with no family history of the disease.

Medullary carcinoma is typically more aggressive than other types of thyroid cancer and tends to spread (metastasize) to other parts of the body, such as the lymph nodes, lungs, and liver. Symptoms may include a lump or nodule in the neck, difficulty swallowing, hoarseness, and coughing. Treatment options may include surgery, radiation therapy, and chemotherapy. Regular monitoring of calcitonin levels is also recommended to monitor the effectiveness of treatment and detect any recurrence of the disease.

Emission-Computed Tomography, Single-Photon (SPECT) is a type of nuclear medicine imaging procedure that generates detailed, three-dimensional images of the distribution of radioactive pharmaceuticals within the body. It uses gamma rays emitted by a radiopharmaceutical that is introduced into the patient's body, and a specialized gamma camera to detect these gamma rays and create tomographic images. The data obtained from the SPECT imaging can be used to diagnose various medical conditions, evaluate organ function, and guide treatment decisions. It is commonly used to image the heart, brain, and bones, among other organs and systems.

Chelating agents are substances that can bind and form stable complexes with certain metal ions, preventing them from participating in chemical reactions. In medicine, chelating agents are used to remove toxic or excessive amounts of metal ions from the body. For example, ethylenediaminetetraacetic acid (EDTA) is a commonly used chelating agent that can bind with heavy metals such as lead and mercury, helping to eliminate them from the body and reduce their toxic effects. Other chelating agents include dimercaprol (BAL), penicillamine, and deferoxamine. These agents are used to treat metal poisoning, including lead poisoning, iron overload, and copper toxicity.

Drug delivery systems (DDS) refer to techniques or technologies that are designed to improve the administration of a pharmaceutical compound in terms of its efficiency, safety, and efficacy. A DDS can modify the drug release profile, target the drug to specific cells or tissues, protect the drug from degradation, and reduce side effects.

The goal of a DDS is to optimize the bioavailability of a drug, which is the amount of the drug that reaches the systemic circulation and is available at the site of action. This can be achieved through various approaches, such as encapsulating the drug in a nanoparticle or attaching it to a biomolecule that targets specific cells or tissues.

Some examples of DDS include:

1. Controlled release systems: These systems are designed to release the drug at a controlled rate over an extended period, reducing the frequency of dosing and improving patient compliance.
2. Targeted delivery systems: These systems use biomolecules such as antibodies or ligands to target the drug to specific cells or tissues, increasing its efficacy and reducing side effects.
3. Nanoparticle-based delivery systems: These systems use nanoparticles made of polymers, lipids, or inorganic materials to encapsulate the drug and protect it from degradation, improve its solubility, and target it to specific cells or tissues.
4. Biodegradable implants: These are small devices that can be implanted under the skin or into body cavities to deliver drugs over an extended period. They can be made of biodegradable materials that gradually break down and release the drug.
5. Inhalation delivery systems: These systems use inhalers or nebulizers to deliver drugs directly to the lungs, bypassing the digestive system and improving bioavailability.

Overall, DDS play a critical role in modern pharmaceutical research and development, enabling the creation of new drugs with improved efficacy, safety, and patient compliance.

Antineoplastic agents are a class of drugs used to treat malignant neoplasms or cancer. These agents work by inhibiting the growth and proliferation of cancer cells, either by killing them or preventing their division and replication. Antineoplastic agents can be classified based on their mechanism of action, such as alkylating agents, antimetabolites, topoisomerase inhibitors, mitotic inhibitors, and targeted therapy agents.

Alkylating agents work by adding alkyl groups to DNA, which can cause cross-linking of DNA strands and ultimately lead to cell death. Antimetabolites interfere with the metabolic processes necessary for DNA synthesis and replication, while topoisomerase inhibitors prevent the relaxation of supercoiled DNA during replication. Mitotic inhibitors disrupt the normal functioning of the mitotic spindle, which is essential for cell division. Targeted therapy agents are designed to target specific molecular abnormalities in cancer cells, such as mutated oncogenes or dysregulated signaling pathways.

It's important to note that antineoplastic agents can also affect normal cells and tissues, leading to various side effects such as nausea, vomiting, hair loss, and myelosuppression (suppression of bone marrow function). Therefore, the use of these drugs requires careful monitoring and management of their potential adverse effects.

The Lewis blood-group system is one of the human blood group systems, which is based on the presence or absence of two antigens: Lea and Leb. These antigens are carbohydrate structures that can be found on the surface of red blood cells (RBCs) as well as other cells and in various body fluids.

The Lewis system is unique because its antigens are not normally present at birth, but instead develop during early childhood or later in life due to the action of certain enzymes in the digestive tract. The production of Lea and Leb antigens depends on the activity of two genes, FUT3 (also known as Lewis gene) and FUT2 (also known as Secretor gene).

There are four main phenotypes or blood types in the Lewis system:

1. Le(a+b-): This is the most common phenotype, where individuals have both Lea and Leb antigens on their RBCs.
2. Le(a-b+): In this phenotype, individuals lack the Lea antigen but have the Leb antigen on their RBCs.
3. Le(a-b-): This is a rare phenotype where neither Lea nor Leb antigens are present on the RBCs.
4. Le(a+b+): In this phenotype, individuals have both Lea and Leb antigens on their RBCs due to the simultaneous expression of FUT3 and FUT2 genes.

The Lewis blood-group system is not typically associated with transfusion reactions or hemolytic diseases, unlike other blood group systems such as ABO and Rh. However, the presence or absence of Lewis antigens can still have implications for certain medical conditions and tests, including:

* Infectious diseases: Some bacteria and viruses can use the Lewis antigens as receptors to attach to and infect host cells. For example, Helicobacter pylori, which causes gastritis and peptic ulcers, binds to Lea antigens in the stomach.
* Autoimmune disorders: In some cases, autoantibodies against Lewis antigens have been found in patients with autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus (SLE).
* Pregnancy: The Lewis antigens can be expressed on the surface of placental cells, and changes in their expression have been linked to pregnancy complications such as preeclampsia and fetal growth restriction.
* Blood typing: Although not a primary factor in blood transfusion compatibility, the Lewis blood-group system is still considered when determining the best match for patients who require frequent transfusions or organ transplants.

Immunoglobulin G (IgG) is a type of antibody, which is a protective protein produced by the immune system in response to foreign substances like bacteria or viruses. IgG is the most abundant type of antibody in human blood, making up about 75-80% of all antibodies. It is found in all body fluids and plays a crucial role in fighting infections caused by bacteria, viruses, and toxins.

IgG has several important functions:

1. Neutralization: IgG can bind to the surface of bacteria or viruses, preventing them from attaching to and infecting human cells.
2. Opsonization: IgG coats the surface of pathogens, making them more recognizable and easier for immune cells like neutrophils and macrophages to phagocytose (engulf and destroy) them.
3. Complement activation: IgG can activate the complement system, a group of proteins that work together to help eliminate pathogens from the body. Activation of the complement system leads to the formation of the membrane attack complex, which creates holes in the cell membranes of bacteria, leading to their lysis (destruction).
4. Antibody-dependent cellular cytotoxicity (ADCC): IgG can bind to immune cells like natural killer (NK) cells and trigger them to release substances that cause target cells (such as virus-infected or cancerous cells) to undergo apoptosis (programmed cell death).
5. Immune complex formation: IgG can form immune complexes with antigens, which can then be removed from the body through various mechanisms, such as phagocytosis by immune cells or excretion in urine.

IgG is a critical component of adaptive immunity and provides long-lasting protection against reinfection with many pathogens. It has four subclasses (IgG1, IgG2, IgG3, and IgG4) that differ in their structure, function, and distribution in the body.

Linear Energy Transfer (LET) is a concept in radiation physics that describes the amount of energy that is transferred from an ionizing particle to a medium per unit length along its path. It is usually expressed in units of keV/μm (kiloelectron volts per micrometer). High-LET radiations, such as alpha particles and heavy ions, transfer more energy to the medium per unit length than low-LET radiations, such as X-rays and gamma rays. This results in a higher probability of producing dense ionizations and causing biological damage along the particle's path. Therefore, LET is an important factor in determining the relative biological effectiveness (RBE) of different types of radiation.

CD45 is a protein that is found on the surface of many types of white blood cells, including T-cells, B-cells, and natural killer (NK) cells. It is also known as leukocyte common antigen because it is present on almost all leukocytes. CD45 is a tyrosine phosphatase that plays a role in regulating the activity of various proteins involved in cell signaling pathways.

As an antigen, CD45 is used as a marker to identify and distinguish different types of white blood cells. It has several isoforms that are generated by alternative splicing of its mRNA, resulting in different molecular weights. The size of the CD45 isoform can be used to distinguish between different subsets of T-cells and B-cells.

CD45 is an important molecule in the immune system, and abnormalities in its expression or function have been implicated in various diseases, including autoimmune disorders and cancer.

Neoplasms are abnormal growths of cells or tissues in the body that serve no physiological function. They can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slow growing and do not spread to other parts of the body, while malignant neoplasms are aggressive, invasive, and can metastasize to distant sites.

Neoplasms occur when there is a dysregulation in the normal process of cell division and differentiation, leading to uncontrolled growth and accumulation of cells. This can result from genetic mutations or other factors such as viral infections, environmental exposures, or hormonal imbalances.

Neoplasms can develop in any organ or tissue of the body and can cause various symptoms depending on their size, location, and type. Treatment options for neoplasms include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy, among others.

Colorectal neoplasms refer to abnormal growths in the colon or rectum, which can be benign or malignant. These growths can arise from the inner lining (mucosa) of the colon or rectum and can take various forms such as polyps, adenomas, or carcinomas.

Benign neoplasms, such as hyperplastic polyps and inflammatory polyps, are not cancerous but may need to be removed to prevent the development of malignant tumors. Adenomas, on the other hand, are precancerous lesions that can develop into colorectal cancer if left untreated.

Colorectal cancer is a malignant neoplasm that arises from the uncontrolled growth and division of cells in the colon or rectum. It is one of the most common types of cancer worldwide and can spread to other parts of the body through the bloodstream or lymphatic system.

Regular screening for colorectal neoplasms is recommended for individuals over the age of 50, as early detection and removal of precancerous lesions can significantly reduce the risk of developing colorectal cancer.

Samarium is not a medical term itself, but it is a chemical element with the symbol Sm and atomic number 62. It is a silvery-white metallic element that belongs to the lanthanide series in the periodic table.

However, samarium-153 (Sm-153) is a radioactive isotope of samarium that has medical applications. It is used as a therapeutic agent for the treatment of painful bone metastases, particularly in patients with prostate or breast cancer. Sm-153 is combined with a chelating agent to form a complex that can be injected into the patient's bloodstream. The chelating agent helps to ensure that the samarium is distributed throughout the body and is not taken up by healthy tissues. Once inside the body, Sm-153 emits beta particles, which can destroy cancer cells in the bones and relieve pain.

Therefore, while samarium is not a medical term itself, it does have medical applications as a therapeutic agent for the treatment of bone metastases.

A hapten is a small molecule that can elicit an immune response only when it is attached to a larger carrier protein. On its own, a hapten is too small to be recognized by the immune system as a foreign substance. However, when it binds to a carrier protein, it creates a new antigenic site that can be detected by the immune system. This process is known as haptenization.

Haptens are important in the study of immunology and allergies because they can cause an allergic response when they bind to proteins in the body. For example, certain chemicals found in cosmetics, drugs, or industrial products can act as haptens and trigger an allergic reaction when they come into contact with the skin or mucous membranes. The resulting immune response can cause symptoms such as rash, itching, or inflammation.

Haptens can also be used in the development of vaccines and diagnostic tests, where they are attached to carrier proteins to stimulate an immune response and produce specific antibodies that can be measured or used for therapy.

... of leukemia. Adv Pharmacol. 2004;51:185-208. Quang TS, Brady LW. Radioimmunotherapy as a novel treatment ... Radioimmunotherapy (RIT) uses an antibody labeled with a radionuclide to deliver cytotoxic radiation to a target cell. It is a ... Radioimmunotherapy of prostate cancer. Q J Nucl Med Mol Imaging. 2004 Dec;48(4):297-304. Dadachova E, Nosanchuk JD, Shi L, ... A set of radioimmunotherapy drugs that rely upon an alpha-emitting isotope (e.g., bismuth-213 or, preferably, actinium-225), ...
Larson, Steven M.; Carrasquillo, Jorge A.; Cheung, Nai-Kong V.; Press, Oliver W. (22 May 2015). "Radioimmunotherapy of human ... Seidl, Christof (April 2014). "Radioimmunotherapy with α-particle-emitting radionuclides". Immunotherapy. 6 (4): 431-458. doi: ...
Mausner, Leonard F. (1993). "Selection of radionuclides for radioimmunotherapy". Medical Physics. 20 (2): 503-509. Bibcode: ...
Sharkey, Robert M.; Goldenberg, David M. (2006-01-01). "Advances in Radioimmunotherapy in the Age of Molecular Engineering and ... "Pretargeted radioimmunotherapy of cancer: progress step by step". Journal of Nuclear Medicine. 44 (3): 400-411. ISSN 0161-5505 ... in the mid-1980s a strategy called pretargeted radioimmunotherapy was developed. In short, this approach contained two ... "Recombinant Bispecific Monoclonal Antibodies Prepared by the Dock-and-Lock Strategy for Pretargeted Radioimmunotherapy". ...
Seidl, C (2014). "Radioimmunotherapy with α-particle-emitting radionuclides". Immunotherapy. 6 (4): 431-58. doi:10.2217/imt. ...
Chinol M, Hnatowich DJ (September 1987). "Generator-produced yttrium-90 for radioimmunotherapy". Journal of Nuclear Medicine. ...
In pretargeted radioimmunotherapy, two or three medications are applied in succession. At first, an antibody-drug conjugate is ... It is used experimentally in pretargeted radioimmunotherapy. Animal studies have been conducted as well as clinical studies in ... Domingo RJ; Reilly RM (2000). "Pre-targeted radioimmunotherapy of human colon cancer xenografts in athymic mice using ... May 2011). "Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival ...
"Integrin-αvβ3 Targeted Radioimmunotherapy of Glioblastoma Multiforme". Clinical Cancer Research. 14 (22): 7330-9. doi:10.1158/ ...
When the conjugates include a radioisotope see radioimmunotherapy. When the conjugates include a toxin see immunotoxin. ...
Radioimmunotherapy of metastatic melanoma is currently under investigation. Radiotherapy has a role in the palliation of ...
"Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies". Journal of Nuclear Medicine. 53 (6): ...
"Production of actinium-225 for alpha particle mediated radioimmunotherapy". Applied Radiation and Isotopes. 62 (5): 667-679. ...
Factors influencing the effect of radioimmunotherapy on liver cancer. Chinese Journal of Cancer Research 4(2):55-60, 1992, ...
Tositumomab, an alternative radioimmunotherapy treatment for non-Hodgkin's lymphoma. Official Zevalin site "Ibritumomab ... WHO Drug Information Schaefer NG, Huang P, Buchanan JW, Wahl RL (May 2011). "Radioimmunotherapy in non-Hodgkin lymphoma: ... Developed by the IDEC Pharmaceuticals, now part of Biogen Idec, ibritumomab tiuxetan was the first radioimmunotherapy drug ... Grillo-López AJ (October 2002). "Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma". Expert Review ...
There are four classes of treatments in general use: chemotherapy, immunotherapy, radioimmunotherapy and biologic agents. The ... There are newer[when?] variations on monoclonal antibodies combined with radioactive molecules known as radioimmunotherapy. ...
Davies, A J (28 May 2007). "Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab". Oncogene. ...
Wu C, Brechbiel MW, Kozak RW, Gansow OA (1994). "Metal-chelate-dendrimer-antibody constructs for use in radioimmunotherapy and ...
Alternatively, in radioimmunotherapy a radioactive dose localizes a target cell line, delivering lethal chemical doses. ... Radioimmunotherapy (RIT) involves the use of radioactively-conjugated murine antibodies against cellular antigens. Most ...
"Defining Pharmacokinetics for Individual Patient Dosimetry in Routine Radiopeptide and Radioimmunotherapy of Cancer: Australian ...
October 2003). "Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer ...
"Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma". ...
For cancers that highly express CEA, targeting CEA through radioimmunotherapy is one of the therapy approaches. Engineered ... radioimmunotherapy in patients with metastatic CEA-producing malignancies". Cancer Biotherapy & Radiopharmaceuticals. 21 (2): ...
July 2005). "Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized ...
Domingo, R. J.; Reilly, R. M. (2000). "Pre-targeted radioimmunotherapy of human colon cancer xenografts in athymic mice using ...
... integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts". Cancer ...
These medications were the first agents of what is known as radioimmunotherapy, and they were approved for the treatment of ...
These include: ofatumumab, a monoclonal antibody that is stronger than rituximab in binding to CD20; two radioimmunotherapy ...
... radioimmunotherapy MeSH E02.095.682.884 - tissue therapy MeSH E02.120.285.570 - leukapheresis MeSH E02.120.285.790 - ...
... as a radioimmunotherapy agent, and in combination with chemotherapy. Establishment of the autologous typing system as the ...
... and radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin) & 131I tositumomab (Bexxar) therapy of low-grade non-Hodgkin's ...
Radioimmunotherapy of leukemia. Adv Pharmacol. 2004;51:185-208. Quang TS, Brady LW. Radioimmunotherapy as a novel treatment ... Radioimmunotherapy (RIT) uses an antibody labeled with a radionuclide to deliver cytotoxic radiation to a target cell. It is a ... Radioimmunotherapy of prostate cancer. Q J Nucl Med Mol Imaging. 2004 Dec;48(4):297-304. Dadachova E, Nosanchuk JD, Shi L, ... A set of radioimmunotherapy drugs that rely upon an alpha-emitting isotope (e.g., bismuth-213 or, preferably, actinium-225), ...
... and the results indicate that radioimmunotherapy is more effective than either radiotherapy or immunotherapy alone. ... Dynamics of an Antitumour Model with Pulsed Radioimmunotherapy. Gang Wang. ,1Ming Yi. ,2and Sanyi Tang. 3 ... Numerous studies have shown that radioimmunotherapy is more effective for inhibiting tumour growth than radiotherapy [4, 20]. ... are determined through numerical simulations, and the results indicate that radioimmunotherapy is more effective than either ...
... named in this special issue radioimmunotherapy. However, one has always to keep in mind that many challenges do still exist ... Editorial: Radioimmunotherapy-Translational Opportunities and Challenges. Udo S. Gaipl1* Gabriele Multhoff2 A. Graham Pockley3 ... Immune modulatory effects of radiotherapy as basis for well-reasoned radioimmunotherapies. Strahlenther Onkol. (2018) 194:509- ... This again high lights the huge translational opportunities of radioimmunotherapies (Palata et al.). Besides cytokines, active ...
Health Canada has approved a new treatment that could offer hope for those who suffer from what is considered an incurable form of non-Hodgkins lymphoma (NHL) and who have failed on, or relapsed following, other treatments. Health Canada approved Bexxar(TM) (tositumomab and iodine I 131 tositumomab) therapy for the treatment of patients with CD20 positive relapsed or
Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. Gynecol Oncol. 1997;65:94-101. ... Dose Escalation and Dosimetry of First-in-Human α Radioimmunotherapy with 212Pb-TCMC-Trastuzumab. Ruby Meredith, Julien Torgue ... Intracavitary radioimmunotherapy to treat solid tumors. Cancer Biother Radiopharm. 2008;23:92-107. ... A strategy to reduce red marrow dose for intraperitoneal radioimmunotherapy. Clin Cancer Res. 1999;5:3044s-3047s. ...
Radioimmunotherapy (RIT) is a treatment for cancer which combines radiation and immune therapy using monoclonal antibodies. RIT ... A Model-Based Approach for the Optimization of Radioimmunotherapy through Antibody Design and Radionuclide Selection, Aiden A. ... A Model-Based Approach for the Optimization of Radioimmunotherapy through Antibody Design and Radionuclide Selection ... A Model-Based Approach for the Optimization of Radioimmunotherapy through Antibody Design and Radionuclide Selection ...
... ... Intraperitoneal radioimmunotherapy with an 211At-labelled specific antibody is an effective treatment of human ovarian cancer ... Thus there is a great need for consolidating therapy.Radioimmunotherapy (RIT), i.e. treatment with specific monoclonal ...
Targeted Radioimmunotherapy. Follicular lymphoma is inherently radiosensitive, so the development of targeted ... Other first-line treatment options include rituximab, alone or in combination with other agents, and radioimmunotherapy ... Combination treatment with involved-field radiation therapy (IFRT) and chemotherapy (see below) and/or radioimmunotherapy is ... What is the role of targeted radioimmunotherapy in the treatment of follicular lymphoma? ...
... Grana, Chiara Maria. Primo. ;Paganelli, Giovanni. Ultimo. 2013. Abstract. Gliomas and ... trials in brain tumors have almost exclusively exploited the potential of radioimmunotherapy (RIT) by employing a radiolabeled ... trials in brain tumors have almost exclusively exploited the potential of radioimmunotherapy (RIT) by employing a radiolabeled ...
Targeted Radioimmunotherapy. Follicular lymphoma is inherently radiosensitive, so the development of targeted ... Other first-line treatment options include rituximab, alone or in combination with other agents, and radioimmunotherapy ... Combination treatment with involved-field radiation therapy (IFRT) and chemotherapy (see below) and/or radioimmunotherapy is ... What is the role of targeted radioimmunotherapy in the treatment of follicular lymphoma? ...
Radioimmunotherapy of solid tumors targeting a cell-surface protein, FZD10: therapeutic efficacy largely depends on ... Radioimmunotherapy of solid tumors targeting a cell-surface protein, FZD10: therapeutic efficacy largely depends on ... Radioimmunotherapy of solid tumors targeting a cell-surface protein, FZD10: therapeutic efficacy largely depends on ...
We aim to expedite the clinical translation of the developed radioimmunotherapy approaches by investigating the early ... Methods: Mice bearing BxPC3 tumor xenografts were treated with α- and β-particle pretargeted radioimmunotherapy (PRIT), ... DNA damage, PET, Radioimmunotherapy, pancreatic cancer, γH2AX, Alpha Particles, Animals, Antigens, Tumor-Associated, ... We aim to expedite the clinical translation of the developed radioimmunotherapy approaches by investigating the early ...
Radioimmunotherapy with alpha-emitting nuclides journal, September 1998 * McDevitt, Michael R.; Sgouros, George; Finn, Ronald D ...
Radioimmunotherapy cures human non-Hodgkin lymphoma in animal model A new nuclear medicine therapy can cure human non-Hodgkin ...
Radioimmunotherapy with an 211At-labeled anti-tissue factor antibody protected by sodium ascorbate. In: Cancer Science. 2021 ; ... Radioimmunotherapy with an 211At-labeled anti-tissue factor antibody protected by sodium ascorbate. Cancer Science. 2021 May; ... Radioimmunotherapy with an 211At-labeled anti-tissue factor antibody protected by sodium ascorbate. / Takashima, Hiroki; Koga, ... Radioimmunotherapy with an 211At-labeled anti-tissue factor antibody protected by sodium ascorbate. ...
Integrated Treatment Planning System To Calculate Three Dimensional Absorbed Dose For Radio-Immunotherapy. Title. Integrated ... Treatment Planning System To Calculate Three Dimensional Absorbed Dose For Radio-Immunotherapy. Publication Type. Conference ...
Combination radio-immunotherapy against 9464D-GD2 neuroblastoma tumors: some small tumors are cured, but not larger tumors. ... We recently described an effective combination radio-immunotherapy treatment regimen (combination adaptive-innate immunotherapy ... A combination radio-immunotherapy regimen (external beam radiotherapy, hu14.18-IL2 immunocytokine, CpG, anti-CD40, and anti- ... We previously described a combination radio-immunotherapy regimen (CAIR) that is effective in 9464D-GD2 tumors (figure 1A).4 We ...
Radioimmunotherapy. Sofia Frost, Tom Bäck, Nicolas Chouin, Holger Jensen, Ragnar Hultborn, Lars Jacobsson, Sture Lindegren ... Repeated Intraperitoneal alpha-Radioimmunotherapy of Ovarian Cancer in Mice. Jörgen Elgqvist, Håkan Andersson, Holger Jensen, ... Intraperitoneal alpha-radioimmunotherapy in mice using different specific activities. Jörgen Elgqvist, Håkan Andersson, Elin ... Intraperitoneal alpha-radioimmunotherapy of ovarian cancer - pharmacokinetics and dosimetry of 211At-MX35 F(ab)2 in a phase I ...
Radioimmunotherapy (RIT) (American College of Radiology; Radiological Society of North America) Also in Spanish ...
Stapled liposomes enhance cross-priming of radio-immunotherapy. Adv. Mater. (Deerfield Beach, Fla.) 34, e2107161 (2022). ... FLT3L release by natural killer cells enhances response to radioimmunotherapy in preclinical models of HNSCC. Clin. Cancer Res. ... Metabolic homeostasis-regulated nanoparticles for antibody-independent cancer radio-immunotherapy. Adv. Mater. 34, e2207343 ( ... Metal-cyclic dinucleotide nanomodulator-stimulated STING signaling for strengthened radioimmunotherapy of large tumor. Small ( ...
The objective of this study was to evaluate the potential of targeting CD138 by immuno-PET imaging and radioimmunotherapy (RIT ... From: Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A ...
0267: Potential of Bi-213-Pankomab for Radioimmuno- Therapy: in Vitro Cytotoxicity and Biodistribu- Tion in Mice with ... 0267: Potential of Bi-213-Pankomab for Radioimmuno- Therapy: in Vitro Cytotoxicity and Biodistribu- Tion in Mice with ...
Radioimmunotherapy studies in p53-positive HCT116 tumor-bearing mice, receiving either radioimmunotherapy alone or in ... Radioimmunotherapy studies in p53-positive HCT116 tumor-bearing mice, receiving either radioimmunotherapy alone or in ... Radioimmunotherapy studies in p53-positive HCT116 tumor-bearing mice, receiving either radioimmunotherapy alone or in ... Radioimmunotherapy studies in p53-positive HCT116 tumor-bearing mice, receiving either radioimmunotherapy alone or in ...
Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in ... Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in ... MeSH]: Radioimmunotherapy. [DDC subject group]: DDC 610 / Medicine & health. License CC BY-NC 4.0 International. https:// ... of the entire treatment scheme consisting of induction chemoimmunotherapy followed by chemotherapy-free radioimmunotherapy (RIT ...
Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 ... Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 ... Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 ... Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma : Long-term follow-up of a phase 1/2 ...
... with improved efficacy at the higher radioimmunotherapy doses. Conclusions: Fractionated radioimmunotherapy with 90Y-hPAM4 and ... Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic ... 2012). Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced ... 2012). Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced ...
Chief of Radioimmunotherapy, Radiation Oncology. Professor of Radiation Oncology. City of Hope ...
Evaluation of [131I]I- and [177Lu]Lu-DTPA-A11 Minibody for Radioimmunotherapy in a Preclinical Model of PSCA-Expressing ...
New Radioimmunotherapy Cures Epithelial Ovarian Cancer in a Preclinical Study. Sep 15, 2023. AI Identifies Improperly ...
Radioimmunotherapy such as zevalin or Bexxar (tositumomab) can have multiple side effects: infusion reactions such as fevers, ...
  • FIbritumomab Tiuxetan (Zevalinâ„¢) Radioimmunotherapy of Non-Hodgkin's Lymphoma Rao AV, Akabani G, Rizzieri DA. (wikipedia.org)
  • We previously demonstrated that yttrium-90 (Y-90) ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) was safe and effective for relapsed or refractory CD20 + , B-cell, non-Hodgkin lymphoma (NHL). (elsevierpure.com)
  • Radioimmunotherapy such as zevalin or Bexxar (tositumomab) can have multiple side effects: infusion reactions such as fevers, rigors, blood pressure c. (healthtap.com)
  • The change in the stromal compartments of tumors following radiation exposure have to be followed very detailed for future radioimmunotherapy optimization. (frontiersin.org)
  • Although many types of labeled molecules have been investigated for targeted cancer radiotherapy, trials in brain tumors have almost exclusively exploited the potential of radioimmunotherapy (RIT) by employing a radiolabeled monoclonal antibodies (MoAbs) as targeting vehicle. (unife.it)
  • Radioimmunotherapy of solid tumors targeting a cell-surface protein, FZD10: therapeutic efficacy largely depends on radiosensitivity. (uchicago.edu)
  • Radioimmunotherapy has been successfully used in the treatment of lymphoma but thus far has not demonstrated significant efficacy in humans beyond disease stabilization in solid tumors. (wustl.edu)
  • 131I tositumomab and 90Y ibritumomab tiuxetan were the first agents of radioimmunotherapy, and they were approved for the treatment of refractory non-Hodgkin's lymphoma. (wikipedia.org)
  • Radioimmunotherapy (RIT) uses an antibody labeled with a radionuclide to deliver cytotoxic radiation to a target cell. (wikipedia.org)
  • A Phase 1 Dose-escalation Study of Radio- Labeled Antibody, FF-21101(90Y) for the Treatment of Advanced Cancer Smith-Jones PM. Radioimmunotherapy of prostate cancer. (wikipedia.org)
  • Most intraperitoneal radionuclide therapies of ovarian cancer have used β-emitter antibody conjugates (radioimmunotherapy) and have resulted in dose-limiting marrow suppression ( 1 - 10 ). (snmjournals.org)
  • Intraperitoneal radioimmunotherapy with an 211At-labelled specific antibody is an effective treatment of human ovarian cancer growing in nude mice. (gu.se)
  • This information explains when to start taking certain medications before each of your intrathecal radioimmunotherapy (RIT) antibody injections. (mskcc.org)
  • Using their in-house developed or other novel strategies for pre-clinical radioimmunotherapy or radionuclide therapy, LBIC now aim to employ microarrays to investigate cell response and transcriptomic variations in human tumor xenograft models. (lu.se)
  • Additionally, the application of the more radiobiologically potent α emitters such as the 212 Pb/ 212 Bi parent-daughter pair ( 212 Pb half-life, 10.6 h) or 211 At (half-life, 7.2 h) should improve efficacy over prior β-emitter radioimmunotherapy while limiting irradiation of neighboring healthy cells ( 12 ). (snmjournals.org)
  • In addition, efficacy of the entire treatment scheme consisting of induction chemoimmunotherapy followed by chemotherapy-free radioimmunotherapy (RIT) after intratumoral CD8 +immune cell-based patient selection will be analyzed.MethodsPatients with stage III-IVB head and neck squamous cell carcinoma were eligible for this multicenter phase II trial. (uni-ulm.de)
  • We aim to expedite the clinical translation of the developed radioimmunotherapy approaches by investigating the early therapeutic response and effect of radiation therapy in a PDAC mouse model via PET imaging. (ox.ac.uk)
  • Radioimmunotherapy (RIT) is a treatment for cancer which combines radiation and immune therapy using monoclonal antibodies. (cellml.org)
  • Thus there is a great need for consolidating therapy.Radioimmunotherapy (RIT), i.e. treatment with specific monoclonal antibodies (MAb) labelled with radionuclides has been tried for various tumours experimentally and clinically. (gu.se)
  • Components of the extracellular matrix and the tumor microenvironment can also be targeted by radioimmunotherapy, such as Netrin-1 (an axon guidance protein) and FAP (a marker for cancer associated fibroblasts). (wikipedia.org)
  • Methods: Mice bearing BxPC3 tumor xenografts were treated with α- and β-particle pretargeted radioimmunotherapy (PRIT), external beam radiotherapy (EBRT), or sham-treated (vehicle). (ox.ac.uk)
  • Here, we examine the role of p53 in the response to radioimmunotherapy with 64 Cu-DOTA-cetuximab in KRAS-mutated HCT116 tumor-bearing mice, with and without cisplatin, which upregulates wild-type p53. (wustl.edu)
  • Radioimmunotherapy of experimental ovarian cancer with Astatine-211. (gu.se)
  • Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. (springeropen.com)
  • Radioimmunotherapy with 64 Cu was highly effective in a hamster model of colorectal cancer, but targeted radiotherapies with this radionuclide have since not shown as much success. (wustl.edu)
  • LBIC has pioneered the research on radioimmunotherapy and the center provides access to experimental SPECT/CT and PET/CT equipment. (lu.se)
  • 89Zr-PET imaging of DNA double-strand breaks for the early monitoring of response following α- and β-particle radioimmunotherapy in a mouse model of pancreatic ductal adenocarcinoma. (ox.ac.uk)
  • Dr. LaFrance said he hopes to see radioimmunotherapy combined with chemotherapy in earlier stages of disease and in other indications. (medscape.com)
  • It's complicated, it's multifactorial, but I think it's turning the corner that people think combining radioimmunotherapy with chemotherapy is the right thing to do. (medscape.com)
  • 12. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. (nih.gov)
  • A new 225Ac-DOTA-based pre-targeted radioimmunotherapy (PRIT) system has been shown to cure a highly lethal form of advanced intraperitoneal ovarian cancer in a preclinical setting with minimal side effects. (medicalxpress.com)
  • Emerging trends for radioimmunotherapy in solid tumors. (nih.gov)
  • Due to its ability to target both known and occult lesions, radioimmunotherapy (RIT) is an attractive therapeutic modality for solid tumors. (nih.gov)
  • Radioimmunotherapy (RIT) uses an antibody labeled with a radionuclide to deliver cytotoxic radiation to a target cell. (wikipedia.org)
  • Radioimmunotherapy is a form of targeted radionuclide therapy that uses a monoclonal antibody to deliver localized radiation. (nih.gov)
  • 67 Cu (t 1/2 = 62 h) has demonstrated potential as a radionuclide for radioimmunotherapy, but limited availability severely restricts its widespread use. (wustl.edu)
  • Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy. (ucsfhealth.org)
  • 17. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. (nih.gov)
  • These findings suggest the clinical availability of the radioprotectant and applicability of clone 1084 to 211 At-radioimmunotherapy. (elsevierpure.com)
  • Increase in the number of cancer cases and cardiovascular disease, growing demand for targeted cancer treatment dependent on alpha radioimmunotherapy, increasing demand for nuclear imaging techniques, and developments in radiotracer treatment are anticipated to boost the radiopharmaceuticals market size. (prnewswire.com)
  • Copper-Based Nanoscale Coordination Polymers Augmented Tumor Radioimmunotherapy for Immunogenic Cell Death Induction and T-Cell Infiltration. (bvsalud.org)
  • Cite this: Radioimmunotherapy Improves Lymphoma Survival - Medscape - Jun 14, 2013. (medscape.com)
  • One type of radiopharmaceutical is called radioimmunotherapy . (cancer.org)
  • Pretargeting with the affinity enhancement system for radioimmunotherapy. (nih.gov)
  • The extent of relapse correlated with the likelihood of complete response to radioimmunotherapy, Dr. Castellucci reported. (medscape.com)
  • We believe that FDG-PET is a valid tool for evaluating CD20-positive NHL, for both detecting relapse and documenting the response to radioimmunotherapy," he said. (medscape.com)
  • 6. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. (nih.gov)